Narikazu Boku
#144,188
Most Influential Person Now
Researcher
Narikazu Boku's AcademicInfluence.com Rankings
Narikazu Bokucomputer-science Degrees
Computer Science
#7116
World Rank
#7495
Historical Rank
Computational Linguistics
#1361
World Rank
#1376
Historical Rank
Machine Learning
#2529
World Rank
#2563
Historical Rank
Artificial Intelligence
#2815
World Rank
#2859
Historical Rank
Download Badge
Computer Science
Narikazu Boku's Degrees
- PhD Computer Science University of Tokyo
- Masters Computer Science University of Tokyo
- Bachelors Computer Science University of Tokyo
Similar Degrees You Can Earn
Why Is Narikazu Boku Influential?
(Suggest an Edit or Addition)Narikazu Boku's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial (2017) (1426)
- Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer (2012) (965)
- Japanese Society for Cancer of the Colon and Rectum (JSCCR) Guidelines 2014 for treatment of colorectal cancer (2015) (679)
- Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01) (2016) (670)
- Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study. (2009) (575)
- Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: GEST study. (2013) (521)
- Randomized phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: The Japan Clinical Oncology Group Study (JCOG9205). (2003) (418)
- Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 trial. (2013) (411)
- Definitive chemoradiotherapy for T4 and/or M1 lymph node squamous cell carcinoma of the esophagus. (1999) (395)
- Long-term toxicity after definitive chemoradiotherapy for squamous cell carcinoma of the thoracic esophagus. (2003) (344)
- Phase III, randomised trial of avelumab versus physician’s choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction cancer: primary analysis of JAVELIN Gastric 300 (2018) (342)
- Phase II study of chemoradiotherapy with 5-fluorouracil and cisplatin for Stage II-III esophageal squamous cell carcinoma: JCOG trial (JCOG 9906). (2011) (291)
- Esophageal stenosis after endoscopic mucosal resection of superficial esophageal lesions. (2003) (282)
- Phase II study of a combination of irinotecan and cisplatin against metastatic gastric cancer. (1999) (281)
- HER2-positive gastric cancer (2013) (275)
- Phase I/II study of S-1 combined with cisplatin in patients with advanced gastric cancer (2003) (266)
- Comparison of HER2 gene amplification assessed by fluorescence in situ hybridization and HER2 protein expression assessed by immunohistochemistry in gastric cancer. (2006) (243)
- A new technique for endoscopic mucosal resection with an insulated-tip electrosurgical knife improves the completeness of resection of intramucosal gastric neoplasms. (2002) (238)
- A phase II study of single-agent docetaxel in patients with metastatic esophageal cancer. (2004) (224)
- Association of multiple Lugol-voiding lesions with synchronous and metachronous esophageal squamous cell carcinoma in patients with head and neck cancer. (2002) (222)
- Multicenter phase II study of everolimus in patients with previously treated metastatic gastric cancer. (2010) (207)
- Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non-inferiority study (FIRIS study). (2010) (205)
- Nonrandomized comparison between definitive chemoradiotherapy and radical surgery in patients with T(2-3)N(any) M(0) squamous cell carcinoma of the esophagus. (2003) (202)
- Olaparib in combination with paclitaxel in patients with advanced gastric cancer who have progressed following first-line therapy (GOLD): a double-blind, randomised, placebo-controlled, phase 3 trial. (2017) (193)
- Phase II study of sunitinib as second-line treatment for advanced gastric cancer (2010) (187)
- Multicenter retrospective analysis of systemic chemotherapy for advanced neuroendocrine carcinoma of the digestive system (2014) (182)
- A late phase II study of S-1 for metastatic pancreatic cancer (2008) (168)
- Gastrointestinal Oncology Study Group/Japan Clinical Oncology Group : Randomized phase III study of 5-fluorouracil (5-FU) alone versus combination of irinotecan and cisplatin (CP) versus S-1 alone in advanced gastric cancer (JCOG9912) (2007) (158)
- Randomized phase III study of bevacizumab plus FOLFIRI and bevacizumab plus mFOLFOX6 as first-line treatment for patients with metastatic colorectal cancer (WJOG4407G). (2016) (146)
- Safety and efficacy of nivolumab in combination with S-1/capecitabine plus oxaliplatin in patients with previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: interim results of a randomized, phase II trial (ATTRACTION-4) (2018) (145)
- Phase II trial of paclitaxel by three-hour infusion for advanced gastric cancer with short premedication for prophylaxis against paclitaxel-associated hypersensitivity reactions. (2001) (140)
- S-1 monotherapy as first-line treatment in patients with advanced biliary tract cancer: a multicenter phase II study (2008) (139)
- A non-randomized confirmatory trial of an expanded indication for endoscopic submucosal dissection for intestinal-type gastric cancer (cT1a): the Japan Clinical Oncology Group study (JCOG0607) (2017) (138)
- Phase II study of FOLFIRINOX for chemotherapy-naïve Japanese patients with metastatic pancreatic cancer (2014) (134)
- An early phase II study of a 3-hour infusion of paclitaxel for advanced gastric cancer. (1998) (129)
- A phase 3 study of nivolumab in previously treated advanced gastric or gastroesophageal junction cancer (ATTRACTION-2): 2-year update data (2019) (129)
- Weekly paclitaxel as second-line chemotherapy for advanced or recurrent gastric cancer (2006) (127)
- LBA7_PR Nivolumab plus chemotherapy versus chemotherapy alone in patients with previously untreated advanced or recurrent gastric/gastroesophageal junction (G/GEJ) cancer: ATTRACTION-4 (ONO-4538-37) study (2020) (108)
- Biological markers as a predictor for response and prognosis of unresectable gastric cancer patients treated with 5-fluorouracil and cis-platinum. (1998) (107)
- Clinical impact of criteria for complete response (CR) of primary site to treatment of esophageal cancer. (2005) (101)
- Nivolumab (ONO-4538/BMS-936558) as salvage treatment after second or later-line chemotherapy for advanced gastric or gastro-esophageal junction cancer (AGC): A double-blinded, randomized, phase III trial. (2017) (100)
- A phase II trial of a selective c-Met inhibitor tivantinib (ARQ 197) monotherapy as a second- or third-line therapy in the patients with metastatic gastric cancer (2014) (100)
- Efficacy of trastuzumab in Japanese patients with HER2-positive advanced gastric or gastroesophageal junction cancer: a subgroup analysis of the Trastuzumab for Gastric Cancer (ToGA) study (2011) (96)
- Long-term survival and prognostic factors in patients with metastatic gastric cancers treated with chemotherapy in the Japan Clinical Oncology Group (JCOG) study. (2004) (96)
- Phase II study of oxaliplatin plus S-1 as first-line treatment for advanced gastric cancer (G-SOX study). (2010) (91)
- Comparison of the efficacy, toxicity, and pharmacokinetics of a uracil/tegafur (UFT) plus oral leucovorin (LV) regimen between Japanese and American patients with advanced colorectal cancer: joint United States and Japan study of UFT/LV. (2004) (91)
- Randomized phase II study of gemcitabine plus S‐1 versus S‐1 in advanced biliary tract cancer: A Japan Clinical Oncology Group trial (JCOG 0805) (2013) (90)
- Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial. (2022) (89)
- Phase I study of TAS-102 treatment in Japanese patients with advanced solid tumours (2012) (86)
- Randomized Phase III study of 5-fluorouracil continuous infusion vs. sequential methotrexate and 5-fluorouracil therapy in far advanced gastric cancer with peritoneal metastasis (JCOG0106). (2013) (86)
- A multi-center retrospective analysis of survival benefits of chemotherapy for unresectable biliary tract cancer. (2007) (85)
- Randomized Phase III and Extension Studies of Naldemedine in Patients With Opioid-Induced Constipation and Cancer. (2017) (83)
- Phase III Trial of Avelumab Maintenance After First-Line Induction Chemotherapy Versus Continuation of Chemotherapy in Patients With Gastric Cancers: Results From JAVELIN Gastric 100 (2020) (83)
- Palliative radiotherapy for bleeding from advanced gastric cancer: is a schedule of 30 Gy in 10 fractions adequate? (2010) (78)
- Randomized phase III trial of adjuvant chemotherapy with gemcitabine versus S-1 in patients with resected pancreatic cancer: Japan Adjuvant Study Group of Pancreatic Cancer (JASPAC-01). (2008) (78)
- [Bevacizumab (Avastin)]. (2007) (78)
- S-1 as adjuvant chemotherapy for stage III colon cancer: a randomized phase III study (ACTS-CC trial) (2014) (75)
- Evolution of checkpoint inhibitors for the treatment of metastatic gastric cancers: Current status and future perspectives. (2018) (73)
- Management of colon cancer: resource-stratified guidelines from the Asian Oncology Summit 2012. (2012) (73)
- Progression-free survival as a surrogate for overall survival in advanced/recurrent gastric cancer trials: a meta-analysis. (2013) (73)
- EMR as salvage treatment for patients with locoregional failure of definitive chemoradiotherapy for esophageal cancer. (2003) (69)
- Randomized phase II/III clinical trial of elpamotide for patients with advanced pancreatic cancer: PEGASUS-PC Study (2015) (68)
- Docetaxel plus cisplatin and S-1 versus cisplatin and S-1 in patients with advanced gastric cancer (JCOG1013): an open-label, phase 3, randomised controlled trial. (2019) (67)
- Japanese Society of Clinical Oncology clinical practice guidelines 2010 for antiemesis in oncology: executive summary (2015) (66)
- Correlation between immune-related adverse events and prognosis in patients with gastric cancer treated with nivolumab (2019) (66)
- Phase II study of gemcitabine chemotherapy alone for locally advanced pancreatic carcinoma: JCOG0506. (2010) (65)
- Biopsy specimen microvessel density is a useful prognostic marker in patients with T(2-4)M(0) esophageal cancer treated with chemoradiotherapy. (2002) (65)
- Multicenter retrospective study of 132 patients with unresectable small bowel adenocarcinoma treated with chemotherapy. (2012) (64)
- Phase I and pharmacokinetic study of dacomitinib (PF-00299804), an oral irreversible, small molecule inhibitor of human epidermal growth factor receptor-1, -2, and -4 tyrosine kinases, in Japanese patients with advanced solid tumors (2012) (63)
- Randomized phase III trial of adjuvant chemotherapy with gemcitabine versus S-1 for patients with resected pancreatic cancer (JASPAC-01 study). (2013) (63)
- Randomized phase III trial of gastrectomy with or without neoadjuvant S-1 plus cisplatin for type 4 or large type 3 gastric cancer, the short-term safety and surgical results: Japan Clinical Oncology Group Study (JCOG0501) (2019) (63)
- Randomized, Phase II Study of Trastuzumab Beyond Progression in Patients With HER2-Positive Advanced Gastric or Gastroesophageal Junction Cancer: WJOG7112G (T-ACT Study). (2020) (61)
- Safety and efficacy of nivolumab in combination with S-1/capecitabine plus oxaliplatin in patients with previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: interim results of a randomized, phase II trial (ATTRACTION-4). (2019) (61)
- Randomized controlled trial comparing gastrectomy plus chemotherapy with chemotherapy alone in advanced gastric cancer with a single non-curable factor: Japan Clinical Oncology Group Study JCOG 0705 and Korea Gastric Cancer Association Study KGCA01. (2008) (60)
- Therapeutic Drug Monitoring in Oncology: International Association of Therapeutic Drug Monitoring and Clinical Toxicology Recommendations for 5‐Fluorouracil Therapy (2018) (59)
- Analysis of dose-volume histogram parameters for radiation pneumonitis after definitive concurrent chemoradiotherapy for esophageal cancer. (2010) (59)
- S-1 plus leucovorin versus S-1 plus leucovorin and oxaliplatin versus S-1 plus cisplatin in patients with advanced gastric cancer: a randomised, multicentre, open-label, phase 2 trial. (2016) (57)
- Four courses versus eight courses of adjuvant S-1 for patients with stage II gastric cancer (JCOG1104 [OPAS-1]): an open-label, phase 3, non-inferiority, randomised trial. (2019) (56)
- Randomized study of FOLFIRI plus either panitumumab or bevacizumab for wild‐type KRAS colorectal cancer‐WJOG 6210G (2016) (54)
- Surgical Outcome and Prognostic Stratification for Pulmonary Metastasis From Colorectal Cancer. (2017) (54)
- Multicenter phase II study of gemcitabine and S-1 combination therapy (GS Therapy) in patients with metastatic pancreatic cancer. (2007) (53)
- Phase II study of erlotinib plus gemcitabine in Japanese patients with unresectable pancreatic cancer (2011) (52)
- Pretreatment Immune Status Correlates with Progression-Free Survival in Chemotherapy-Treated Metastatic Colorectal Cancer Patients (2016) (52)
- Determination of prognostic factors in Japanese patients with advanced gastric cancer using the data from a randomized controlled trial, Japan clinical oncology group 9912. (2014) (51)
- A Phase II Trial of Combined Treatment of Endoscopic Mucosal Resection and Chemoradiotherapy for Clinical Stage I Esophageal Carcinoma: Japan Clinical Oncology Group Study JCOG0508 (2009) (51)
- Phase 1 study of conatumumab, a pro-apoptotic death receptor 5 agonist antibody, in Japanese patients with advanced solid tumors (2011) (50)
- A multicenter phase II study of S-1 for gemcitabine-refractory biliary tract cancer (2013) (49)
- Present status and perspectives of colorectal cancer in Asia: Colorectal Cancer Working Group report in 30th Asia-Pacific Cancer Conference. (2010) (49)
- JASPAC 01: Randomized phase III trial of adjuvant chemotherapy with gemcitabine versus S-1 for patients with resected pancreatic cancer. (2013) (49)
- Phase I, dose escalation and pharmacokinetic study of cediranib (RECENTIN™), a highly potent and selective VEGFR signaling inhibitor, in Japanese patients with advanced solid tumors (2009) (48)
- Monitoring of cancer patients via next‐generation sequencing of patient‐derived circulating tumor cells and tumor DNA (2019) (47)
- A phase II clinical trial of endoscopic submucosal dissection for early gastric cancer of undifferentiated type: Japan Clinical Oncology Group study JCOG1009/1010. (2013) (46)
- A subanalysis of Japanese patients in a randomized, double-blind, placebo-controlled, phase 3 trial of nivolumab for patients with advanced gastric or gastro-esophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2) (2018) (46)
- Feasibility study of single agent Cisplatin and concurrent radiotherapy in Japanese patients with squamous cell carcinoma of the head and neck: preliminary results. (2007) (46)
- Phase I/II Study of Capecitabine Plus Oxaliplatin (XELOX) Plus Bevacizumab As First-line Therapy in Japanese Patients with Metastatic Colorectal Cancer (2010) (46)
- Outcomes of segmentectomy and wedge resection for pulmonary metastases from colorectal cancer† (2016) (45)
- Safety, efficacy and pharmacokinetics of neratinib (HKI-272) in Japanese patients with advanced solid tumors: a Phase 1 dose-escalation study. (2012) (45)
- Efficacy of chemoradiotherapy on pain relief in patients with intrapelvic recurrence of rectal cancer. (2003) (44)
- Gastrectomy with or without neoadjuvant S-1 plus cisplatin for type 4 or large type 3 gastric cancer (JCOG0501): an open-label, phase 3, randomized controlled trial (2020) (43)
- HERC2 Interacts with Claspin and regulates DNA origin firing and replication fork progression. (2011) (43)
- Chemotherapy for metastatic disease: review from JCOG trials (2008) (43)
- Concurrent chemoradiotherapy for esophageal carcinoma patients with malignant fistulae (1999) (42)
- Weekly paclitaxel for heavily treated advanced or recurrent gastric cancer refractory to fluorouracil, irinotecan, and cisplatin (2009) (42)
- Impact of excision repair cross-complementing gene 1 (ERCC1) on the outcomes of patients with advanced gastric cancer: correlative study in Japan Clinical Oncology Group Trial JCOG9912. (2013) (42)
- Development and Validation of an Esophageal Squamous Cell Carcinoma Detection Model by Large-Scale MicroRNA Profiling (2019) (42)
- Results of the JAVELIN Gastric 100 phase 3 trial: avelumab maintenance following first-line (1L) chemotherapy (CTx) vs continuation of CTx for HER2− advanced gastric or gastroesophageal junction cancer (GC/GEJC). (2020) (42)
- Phase IIb, Randomized, Double-Blind, Placebo-Controlled Study of Naldemedine for the Treatment of Opioid-Induced Constipation in Patients With Cancer. (2017) (41)
- Exploratory subgroup analysis of patients with prior trastuzumab use in the ATTRACTION-2 trial: a randomized phase III clinical trial investigating the efficacy and safety of nivolumab in patients with advanced gastric/gastroesophageal junction cancer (2019) (41)
- Expression profiling of esophageal squamous cell carcinoma patients treated with definitive chemoradiotherapy: clinical implications. (2006) (40)
- Nivolumab in previously treated advanced gastric cancer (ATTRACTION-2): 3-year update and outcome of treatment beyond progression with nivolumab (2021) (40)
- Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer (2017) (40)
- A nonrandomized, single-arm confirmatory trial of expanded endoscopic submucosal dissection indication for undifferentiated early gastric cancer: Japan Clinical Oncology Group study (JCOG1009/1010) (2020) (39)
- Randomized phase III ANGEL study of rivoceranib (apatinib) + best supportive care (BSC) vs placebo + BSC in patients with advanced/metastatic gastric cancer who failed ≥2 prior chemotherapy regimens (2019) (39)
- Comparison of two different S-1 plus cisplatin dosing schedules as first-line chemotherapy for metastatic and/or recurrent gastric cancer: a multicenter, randomized phase III trial (SOS). (2015) (38)
- Hyperprogressive disease during nivolumab or irinotecan treatment in patients with advanced gastric cancer (2019) (37)
- Safety of UFT/LV and S-1 as adjuvant therapy for stage III colon cancer in phase III trial: ACTS-CC trial (2012) (36)
- Japanese Society for Cancer of the Colon and Rectum (JSCCR) Guidelines 2016 for the Clinical Practice of Hereditary Colorectal Cancer (Translated Version) (2018) (36)
- A randomized Phase II trial of systemic chemotherapy with and without trastuzumab followed by surgery in HER2-positive advanced gastric or esophagogastric junction adenocarcinoma with extensive lymph node metastasis: Japan Clinical Oncology Group study JCOG1301 (Trigger Study). (2015) (36)
- Current management of liver metastases from gastric cancer: what is common practice? New challenge of EORTC and JCOG (2017) (34)
- Placebo-Controlled, Double-Blinded Phase III Study Comparing Dexamethasone on Day 1 With Dexamethasone on Days 1 to 3 With Combined Neurokinin-1 Receptor Antagonist and Palonosetron in High-Emetogenic Chemotherapy. (2018) (34)
- A randomized phase II study of weekly paclitaxel ± trastuzumab in patients with HER2-positive advanced gastric or gastro-esophageal junction cancer refractory to trastuzumab combined with fluoropyrimidine and platinum: WJOG7112G (T-ACT). (2018) (34)
- Expression of thymidylate synthase, thymidine phosphorylase, dihydropyrimidine dehydrogenase, E2F-1, Bak, Bcl-X, and Bcl-2, and clinical outcomes for gastric cancer patients treated with bolus 5-fluorouracil. (2004) (34)
- Significance of and problems in adopting response evaluation criteria in solid tumor RECIST for assessing anticancer effects of advanced gastric cancer (2000) (34)
- A randomized phase II study of S-1 plus oral leucovorin versus S-1 monotherapy in patients with gemcitabine-refractory advanced pancreatic cancer† (2015) (34)
- Randomized phase II study of nimotuzumab, an anti-EGFR antibody, plus irinotecan in patients with 5-fluorouracil-based regimen-refractory advanced or recurrent gastric cancer in Korea and Japan: Preliminary results. (2011) (34)
- Optimizing antiemetic treatment for chemotherapy-induced nausea and vomiting in Japan: Update summary of the 2015 Japan Society of Clinical Oncology Clinical Practice Guidelines for Antiemesis (2020) (34)
- Peritoneal metastasis as a predictive factor for nab-paclitaxel in patients with pretreated advanced gastric cancer: an exploratory analysis of the phase III ABSOLUTE trial (2018) (33)
- The usefulness of oral TS-1 treatment for potentially curable gastric cancer patients with intraperitoneal free cancer cells (2006) (32)
- Randomized phase II study of second-line chemotherapy with the best available 5-fluorouracil regimen versus weekly administration of paclitaxel in far advanced gastric cancer with severe peritoneal metastases refractory to 5-fluorouracil-containing regimens (JCOG0407) (2016) (32)
- Risk Factors for Severe Adverse Effects and Treatment-related Deaths in Japanese Patients Treated with Irinotecan-based Chemotherapy: A Postmarketing Survey† (2013) (32)
- The effect of CYP2C19 polymorphism on the safety, tolerability, and pharmacokinetics of tivantinib (ARQ 197): results from a phase I trial in advanced solid tumors. (2013) (31)
- Multicenter Phase II study of cetuximab plus irinotecan in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin and fluoropyrimidines. (2008) (31)
- S-1 monotherapy as second-line treatment for advanced pancreatic cancer after gemcitabine failure. (2010) (30)
- S-1 as adjuvant chemotherapy for stage III colon cancer: a randomized phase III study (ACTS-CC trial). (2014) (30)
- Multicenter phase II study of trastuzumab with S-1 plus oxaliplatin for chemotherapy-naïve, HER2-positive advanced gastric cancer (2019) (30)
- Suppression of T-lymphoma cell apoptosis by monoclonal antibodies raised against cell surface adhesion molecules. (1993) (30)
- Irinotecan monotherapy as third-line treatment for advanced gastric cancer refractory to fluoropyrimidines, platinum, and taxanes (2017) (30)
- A phase II trial of endoscopic submucosal dissection for mucosal gastric cancer: Japan Clinical Oncology Group Study JCOG0607. (2009) (29)
- Correlation between immune-related adverse events and prognosis in patients with gastric cancer treated with nivolumab (2019) (29)
- Efficacy and safety of axitinib in combination with gemcitabine in advanced pancreatic cancer: subgroup analyses by region, including Japan, from the global randomized Phase III trial (2015) (29)
- Sequential methotrexate and 5-fluorouracil therapy for gastric cancer patients with peritoneal dissemination: a retrospective study (2001) (29)
- Five-weekly S-1 plus cisplatin therapy combined with trastuzumab therapy in HER2-positive gastric cancer: a phase II trial and biomarker study (WJOG7212G) (2017) (29)
- Sequential methotrexate and 5-fluorouracil therapy for gastric cancer patients with bone metastasis (2000) (29)
- Prognostic Impact of Palliative Primary Tumor Resection for Unresectable Stage 4 Colorectal Cancer: Using a Propensity Score Analysis (2016) (29)
- Does Repeated Lung Resection Provide Long-Term Survival for Recurrent Pulmonary Metastases of Colorectal Cancer? Results of a Retrospective Japanese Multicenter Study. (2017) (28)
- Current status of immunotherapy for advanced gastric cancer. (2020) (28)
- Updated results of randomized phase III study of 5-fluorouracil (5-FU) alone versus combination of irinotecan and cisplatin (CP) versus S-1 alone in advanced gastric cancer (JCOG 9912). (2009) (28)
- Phase 1 study of ganitumab (AMG 479), a fully human monoclonal antibody against the insulin-like growth factor receptor type I (IGF1R), in Japanese patients with advanced solid tumors (2012) (28)
- Survival impact of post-progression chemotherapy in advanced gastric cancer: systematic review and meta-analysis (2018) (28)
- Biological markers as a predictor for response and prognosis of unresectable gastric cancer patients treated with irinotecan and cisplatin. (2005) (28)
- Sunitinib as second-line treatment for advanced gastric cancer: preliminary results from a phase II study (2007) (28)
- Phase I dose-escalation study of the HSP90 inhibitor AUY922 in Japanese patients with advanced solid tumors (2014) (28)
- Phase I study of single-dose oxaliplatin in Japanese patients with malignant tumors. (2006) (28)
- S-1 plus leucovorin and oxaliplatin versus S-1 plus cisplatin as first-line therapy in patients with advanced gastric cancer (SOLAR): a randomised, open-label, phase 3 trial. (2020) (28)
- Single-agent docetaxel in patients with platinum-refractory metastatic or recurrent squamous cell carcinoma of the head and neck (SCCHN). (2007) (27)
- Randomized phase III study of irinotecan (CPT-11) versus weekly paclitaxel (wPTX) for advanced gastric cancer (AGC) refractory to combination chemotherapy (CT) of fluoropyrimidine plus platinum (FP): WJOG4007 trial. (2012) (27)
- A retrospective analysis of 5-fluorouracil plus cisplatin as first-line chemotherapy in the recent treatment strategy for patients with metastatic or recurrent esophageal squamous cell carcinoma (2018) (27)
- Prognostic Value of Primary Tumor Sidedness for Unresectable Stage IV Colorectal Cancer: A Retrospective Study (2019) (26)
- Efficacy and safety of capecitabine plus cisplatin in Japanese patients with advanced or metastatic gastric cancer: subset analyses of the AVAGAST study and the ToGA study (2012) (26)
- Efficacy of sequential methotrexate and 5-fluorouracil (MTX/5FU) in improving oral intake in patients with advanced gastric cancer with severe peritoneal dissemination (2009) (26)
- Regional differences in advanced gastric cancer: exploratory analyses of the AVAGAST placebo arm (2017) (26)
- Survival Benefit of Palliative Gastrectomy in Gastric Cancer Patients with Peritoneal Metastasis (2012) (25)
- Prognostic factors of brain metastases from colorectal cancer (2019) (25)
- Phase I/II study of ramucirumab plus nivolumab in patients in second-line treatment for advanced gastric adenocarcinoma (NivoRam study). (2019) (25)
- Adjuvant therapy with imatinib mesylate after resection of primary high-risk gastrointestinal stromal tumors in Japanese patients (2013) (25)
- Impact of hemoglobin level on survival in definitive chemoradiotherapy for T4/M1 lymph node esophageal cancer. (2008) (25)
- Checkmate 649: A randomized, multicenter, open-label, phase 3 study of nivolumab (Nivo) plus ipilimumab (Ipi) versus oxaliplatin plus fluoropyrimidine in patients (Pts) with previously untreated advanced or metastatic gastric (G) or gastroesophageal junction (GEJ) cancer. (2017) (25)
- Phase I study of cediranib in combination with cisplatin plus fluoropyrimidine (S-1 or capecitabine) in Japanese patients with previously untreated advanced gastric cancer (2012) (25)
- 617OA Phase 3 Study of nivolumab (Nivo) in previously treated advanced gastric or gastroesophageal junction (G/GEJ) cancer: Updated results and subset analysis by PD-L1 expression (ATTRACTION-02) (2017) (25)
- Phase I study of TAS-102 and irinotecan combination therapy in Japanese patients with advanced colorectal cancer (2015) (25)
- Hepatic arterial infusion of 5-fluorouracil for patients with liver metastases from colorectal cancer refractory to standard systemic chemotherapy: a multicenter, retrospective analysis. (2010) (24)
- Small-cell carcinoma in the common bile duct treated with multidisciplinary management. (2009) (24)
- CheckMate 649: A randomized, multicenter, open-label, phase III study of nivolumab (NIVO) + ipilimumab (IPI) or nivo + chemotherapy (CTX) versus CTX alone in patients with previously untreated advanced (Adv) gastric (G) or gastroesophageal junction (GEJ) cancer. (2017) (24)
- Phase II study of the effectiveness and safety of trastuzumab and paclitaxel for taxane‐ and trastuzumab‐naïve patients with HER2‐positive, previously treated, advanced, or recurrent gastric cancer (JFMC45‐1102) (2016) (24)
- Phase II study of S-1 plus leucovorin in patients with metastatic colorectal cancer (2009) (24)
- Chemotherapy for metastatic gastric cancer in Japan (2008) (24)
- Impact of dihydropyrimidine dehydrogenase status of biopsy specimens on efficacy of irinotecan plus cisplatin, S-1, or 5-FU as first-line treatment of advanced gastric cancer patients in JCOG9912. (2016) (23)
- Panitumumab in Japanese Patients with Unresectable Colorectal Cancer: A Post-marketing Surveillance Study of 3085 Patients† (2014) (23)
- Risk factors and clinical courses of chemoradiation-related arterio-esophageal fistula in esophageal cancer patients with clinical invasion of the aorta (2011) (23)
- A phase II study of uracil-tegafur plus doxorubicin and prognostic factors in patients with unresectable biliary tract cancer (2009) (23)
- Value of KRAS, BRAF, and PIK3CA Mutations and Survival Benefit from Systemic Chemotherapy in Colorectal Peritoneal Carcinomatosis. (2016) (23)
- A phase I study of intravenous aflibercept with FOLFIRI in Japanese patients with previously treated metastatic colorectal cancer (2012) (23)
- Survival prolongation after treatment failure of first-line chemotherapy in patients with advanced gastric cancer: combined analysis of the Japan Clinical Oncology Group Trials JCOG9205 and JCOG9912 (2013) (23)
- Phase I/II trial of chemoradiotherapy with concurrent S-1 and cisplatin for clinical stage II/III esophageal carcinoma (JCOG 0604) (2015) (23)
- Randomized Phase III Study of 5-Fluorouracil Continuous Infusion vs . Sequential Methotrexate and 5-Fluorouracil Therapy in Far Advanced Gastric Cancer with Peritoneal Metastasis ( JCOG 0106 ) (2013) (23)
- Updated results from GEST study: a randomized, three-arm phase III study for advanced pancreatic cancer (2017) (23)
- Multi-omic profiling of peritoneal metastases in gastric cancer identifies molecular subtypes and therapeutic vulnerabilities (2021) (23)
- A Phase II study of systemic chemotherapy with docetaxel, cisplatin, and S-1 (DCS) followed by surgery in gastric cancer patients with extensive lymph node metastasis: Japan Clinical Oncology Group study JCOG1002. (2012) (22)
- A phase I/II study of nedaplatin and 5-fluorouracil with concurrent radiotherapy in patients with T4 esophageal cancer: Japan Clinical Oncology Group trial (JCOG 9908) (2005) (22)
- First report of the safety, tolerability, and pharmacokinetics of the Src kinase inhibitor saracatinib (AZD0530) in Japanese patients with advanced solid tumours (2013) (22)
- Combination chemotherapy with irinotecan and cisplatin in pretreated patients with unresectable or recurrent gastric cancer (2006) (22)
- IL33 Is a Key Driver of Treatment Resistance of Cancer (2020) (22)
- Significance of FGF9 gene in resistance to anti‐EGFR therapies targeting colorectal cancer: A subset of colorectal cancer patients with FGF9 upregulation may be resistant to anti‐EGFR therapies (2017) (21)
- Weekly Paclitaxel after failure of gemcitabine in pancreatic cancer patients with malignant ascites: a retrospective study. (2010) (21)
- Maintenance avelumab versus continuation of first-line chemotherapy in gastric cancer: JAVELIN Gastric 100 study design. (2019) (21)
- Verrucous carcinoma of the esophagus completely resected by endoscopy (2000) (21)
- Leptomeningeal carcinomatosis associated with gastric cancer (2012) (21)
- Phase I/II study of radiologic hepatic arterial infusion of fluorouracil plus systemic irinotecan for unresectable hepatic metastases from colorectal cancer: Japan Clinical Oncology Group Trial 0208-DI. (2012) (20)
- Comparison of safety and efficacy of S-1 monotherapy and S-1 plus cisplatin therapy in elderly patients with advanced gastric cancer (2013) (20)
- Phase II study of gemcitabine chemotherapy alone for locally advanced pancreatic carcinoma: JCOG 0506. (2009) (20)
- Retrospective Analyses of Systemic Chemotherapy and Cytoreductive Surgery for Patients with Ovarian Metastases from Colorectal Cancer: A Single-Center Experience (2018) (20)
- A phase 3 non-inferiority study of 5-FU/l-leucovorin/irinotecan (FOLFIRI) versus irinotecan/S-1 (IRIS) as second-line chemotherapy for metastatic colorectal cancer: updated results of the FIRIS study (2014) (20)
- Phase I study of Efatutazone, an oral PPARγ agonist, in patients with metastatic solid tumors. (2014) (20)
- Survival after failure of first-line chemotherapy in advanced gastric cancer patients: differences between Japan and the rest of the world (2017) (19)
- Health-related quality of life of adjuvant chemotherapy with S-1 versus gemcitabine for resected pancreatic cancer: Results from a randomised phase III trial (JASPAC 01). (2018) (19)
- Shorter survival in adolescent and young adult patients, compared to adult patients, with stage IV colorectal cancer in Japan (2018) (19)
- Factors associated with technical difficulty of endoscopic submucosal dissection for early gastric cancer that met the expanded indication criteria: post hoc analysis of a multi-institutional prospective confirmatory trial (JCOG0607) (2019) (19)
- A phase II study of sequential methotrexate and 5-fluorouracil chemotherapy in previously treated gastric cancer: a report from the Gastrointestinal Oncology Group of the Japan Clinical Oncology Group, JCOG 9207 trial. (2008) (19)
- Occurrence and clinical features of brain metastasis after chemoradiotherapy for esophageal carcinoma. (2011) (19)
- Efficacy and safety profile of S-1 in patients with metastatic gastric cancer in clinical practice: results from a post-marketing survey (2003) (19)
- Efficacy of Postoperative Chemotherapy After Resection that Leaves No Macroscopically Visible Disease of Gastric Cancer with Positive Peritoneal Lavage Cytology (CY1) or Localized Peritoneum Metastasis (P1a): A Multicenter Retrospective Study (2019) (19)
- Neoadjuvant chemotherapy with S-1 for scirrhous gastric cancer: a pilot study (2003) (19)
- Safety and efficacy of S-1 monotherapy in elderly patients with advanced gastric cancer (2010) (18)
- A phase I, pharmacokinetic and pharmacodynamic study of nimotuzumab in Japanese patients with advanced solid tumors (2013) (18)
- Combination chemotherapy of irinotecan plus cisplatin for advanced gastric cancer: efficacy and feasibility in clinical practice (2001) (18)
- A randomized phase III trial of mFOLFOX6 plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment for metastatic colorectal cancer: West Japan Oncology Group study 4407G (WJOG4407G). (2014) (18)
- Relationship between expression of vascular endothelial growth factor in tumor tissue from gastric cancers and chemotherapy effects: comparison between S-1 alone and the combination of S-1 plus CDDP. (2007) (18)
- Safety of bevacizumab treatment in combination with standard chemotherapy for metastatic colorectal cancer: a retrospective review of 65 Japanese patients (2009) (18)
- Phase III randomised trial comparing 6 vs. 12-month of capecitabine as adjuvant chemotherapy for patients with stage III colon cancer: final results of the JFMC37-0801 study (2019) (17)
- Efficacy and feasibility of docetaxel, cisplatin, and 5-fluorouracil induction chemotherapy for locally advanced head and neck squamous cell carcinoma classified as clinical nodal stage N2c, N3, or N2b with supraclavicular lymph node metastases (2015) (17)
- Randomized phase III study of 5-fluorouracil continuous infusion (5FUci) versus methotrexate and 5-FU sequential therapy (MF) in gastric cancer with peritoneal metastasis (JCOG0106). (2016) (17)
- A randomized phase II study of combination therapy with S-1, oral leucovorin, and oxaliplatin (SOL) and mFOLFOX6 in patients with previously untreated metastatic colorectal cancer (2015) (17)
- Phase I results from a two-part Phase I/II study of cediranib in combination with mFOLFOX6 in Japanese patients with metastatic colorectal cancer (2012) (17)
- Identification of serum microRNAs predicting the response of esophageal squamous-cell carcinoma to nivolumab. (2019) (17)
- gastrointestinal tumours, non-colorectalOlaparib in combination with paclitaxel in patients with advanced gastric cancer who have progressed following first-line therapy: Phase III GOLD study (2016) (17)
- Nutritional and inflammatory measures predict survival of patients with stage IV colorectal cancer (2020) (17)
- A phase II study of biweekly mitomycin C and irinotecan combination therapy in patients with fluoropyrimidine-resistant advanced gastric cancer: a report from the Gastrointestinal Oncology Group of the Japan Clinical Oncology Group (JCOG0109-DI Trial) (2011) (17)
- Maintenance therapy with avelumab (MSB0010718C; anti-PD-L1) vs continuation of first-line chemotherapy in patients with unresectable, locally advanced or metastatic gastric cancer: The phase 3 JAVELIN Gastric 100 trial. (2016) (17)
- Randomized phase II study of best-available 5-fluorouracil (5-FU) versus weekly paclitaxel in gastric cancer (GC) with peritoneal metastasis (PM) refractory to 5-FU-containing regimens (JCOG0407). (2010) (17)
- Phase I study of larotaxel administered as a 1-h intravenous infusion every 3 weeks to Japanese patients with advanced solid tumours (2009) (17)
- Validation of the JCOG prognostic index in advanced gastric cancer using individual patient data from the SPIRITS and G-SOX trials (2017) (16)
- The current status of multimodality treatment for unresectable locally advanced esophageal squamous cell carcinoma (2018) (16)
- Infusion site adverse events in breast cancer patients receiving highly emetic chemotherapy with prophylactic anti-emetic treatment with aprepitant and fosaprepitant: A retrospective comparison. (2016) (16)
- Bevacizumab in combination with irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) in patients with metastatic colorectal cancer who were previously treated with oxaliplatin-containing regimens: a multicenter observational cohort study (TCTG 2nd-BV study) (2012) (16)
- Randomized phase III and extension studies: efficacy and impacts on quality of life of naldemedine in subjects with opioid-induced constipation and cancer (2018) (16)
- Comprehensive characterization of the phosphoproteome of gastric cancer from endoscopic biopsy specimens (2020) (16)
- Efficacy of adjuvant chemotherapy after resection of pulmonary metastasis from colorectal cancer: a propensity score-matched analysis. (2019) (16)
- Carcinoma coexisting with esophageal leiomyoma. (2002) (16)
- Phase III trial to evaluate the efficacy of neoadjuvant chemotherapy with S-1 plus oxaliplatin followed by D2 gastrectomy with adjuvant S-1 in locally advanced gastric cancer: Japan Clinical Oncology Group study JCOG1509 (NAGISA trial). (2017) (15)
- Current status of perioperative chemotherapy for locally advanced gastric cancer and JCOG perspectives. (2020) (15)
- Primary Tumor Resection for Stage IV Colorectal Cancer in the Era of Targeted Chemotherapy (2018) (15)
- Randomized Phase III study of 5-fluorouracil alone versus combination of irinotecan and cisplatin versus S-1 alone in advanced gastric cancer (JCOG9912) (2007) (15)
- EGFR and HER2 signals play a salvage role in MEK1-mutated gastric cancer after MEK inhibition. (2015) (15)
- Nutrition Support for Head and Neck Squamous Cell Carcinoma Patients Treated with Chemoradiotherapy: How Often and How Long? (2012) (15)
- SOURCE: A Registry-Based Prediction Model for Overall Survival in Patients with Metastatic Oesophageal or Gastric Cancer (2019) (15)
- Long-term results for patients with unresectable gastric cancer who received chemotherapy in the Japan Clinical Oncology Group (JCOG) trials (2000) (15)
- Association between UGT1A1 gene polymorphism and safety and efficacy of irinotecan monotherapy as the third-line treatment for advanced gastric cancer (2019) (15)
- TAS-118 (S-1 plus leucovorin) versus S-1 in patients with gemcitabine-refractory advanced pancreatic cancer: a randomised, open-label, phase 3 study (GRAPE trial). (2019) (14)
- Randomized phase II trial of gemcitabine plus S-1 combination therapy versus S-1 in advanced biliary tract cancer: Results of the Japan Clinical Oncology Group study (JCOG0805). (2012) (14)
- ATTRACTION-05 (ONO-4538-38/BMS CA209844): a randomized, multicenter, double-blind, placebo-controlled Phase 3 study of Nivolumab (Nivo) in combination with adjuvant chemotherapy in pStage III gastric and esophagogastric junction (G/EGJ) cancer (2017) (14)
- Is postoperative adjuvant chemoradiotherapy necessary for high-risk oropharyngeal squamous cell carcinoma? (2014) (14)
- Efficacy and safety of an irinotecan plus bolus 5-fluorouracil and L-leucovorin regimen for metastatic colorectal cancer in Japanese patients: experience in a single institution in Japan. (2007) (14)
- Multidisciplinary management of stage II-III gastric and gastro-oesophageal junction cancer. (2019) (14)
- Randomized phase II/III study of 5-fluorouracil/l-leucovorin versus 5-fluorouracil/l-leucovorin plus paclitaxel administered to patients with severe peritoneal metastases of gastric cancer (JCOG1108/WJOG7312G) (2020) (14)
- Multicenter retrospective analysis of systemic chemotherapy in poorly differentiated neuroendocrine carcinoma of the digestive system. (2012) (14)
- Phase III study comparing triplet chemotherapy with S-1 and cisplatin plus docetaxel versus doublet chemotherapy with S-1 and cisplatin for advanced gastric cancer (JCOG1013). (2018) (14)
- A phase II study of tivantinib monotherapy in patients with previously treated advanced or recurrent gastric cancer. (2012) (14)
- ATTRACTION-04 (ONO-4538-37): A randomized, multicenter, phase 2/3 study of nivolumab (Nivo) plus chemotherapy in patients (Pts) with previously untreated advanced or recurrent gastric (G) or gastroesophageal junction (GEJ) cancer (2017) (14)
- A Phase II study of irinotecan in combination with 120-h infusion of 5-fluorouracil in patients with metastatic colorectal carcinoma: Japan Clinical Oncology Group Study (JCOG9703). (2003) (14)
- Irinotecan plus cisplatin therapy and S-1 plus cisplatin therapy for advanced or recurrent gastric cancer in a single institution. (2008) (14)
- Phase II trial of concurrent chemoradiotherapy with S-1 plus cisplatin in patients with unresectable locally advanced squamous cell carcinoma of the head and neck: Japan Clinical Oncology Group Study (JCOG0706). (2009) (14)
- Preliminary result of phase 1/2 study of ramucirumab plus nivolumab in patients with previously treated advanced gastric adenocarcinoma (NivoRam study). (2018) (14)
- Nationwide Multicenter Observational Study of FOLFIRINOX Chemotherapy in 399 Patients With Unresectable or Recurrent Pancreatic Cancer in Japan (2018) (13)
- A phase I escalating single-dose and weekly fixed-dose study of cetuximab pharmacokinetics in Japanese patients with solid tumors (2009) (13)
- Outcomes and prognostic factors after pulmonary metastasectomy in patients with colorectal cancer with previously resected hepatic metastases (2019) (13)
- Randomized phase III and extension studies: efficacy and impacts on quality of life of naldemedine in subjects with opioid-induced constipation and cancer (2018) (13)
- Phase II study of oxaliplatin in japanese patients with metastatic colorectal cancer refractory to fluoropyrimidines. (2007) (13)
- Erratum to: Efficacy and safety of capecitabine plus cisplatin in Japanese patients with advanced or metastatic gastric cancer: subset analyses of the AVAGAST study and the ToGA study (2012) (13)
- A Phase II Study of Regorafenib With a Lower Starting Dose in Patients With Metastatic Colorectal Cancer: Exposure-Toxicity Analysis of Unbound Regorafenib and Its Active Metabolites (RESET Trial). (2019) (13)
- Randomized controlled Phase III trial to evaluate omentum preserving gastrectomy for patients with advanced gastric cancer (JCOG1711, ROAD-GC). (2020) (12)
- Patterns of Relapse after Definitive Chemoradiotherapy in Stage II/III (Non-T4) Esophageal Squamous Cell Carcinoma (2017) (12)
- OPTIMAL TIMING OF ENDOSCOPIC EVALUATION OF THE PRIMARY SITE OF ESOPHAGEAL CANCER AFTER CHEMORADIOTHERAPY OR RADIOTHERAPY: A RETROSPECTIVE ANALYSIS (2009) (12)
- A double-blind randomized phase II study of 10 versus 5 mg olanzapine for emesis induced by highly emetogenic chemotherapy with cisplatin. (2016) (12)
- Retrospective analysis of S-1 monotherapy in patients with metastatic colorectal cancer after failure to fluoropyrimidine and irinotecan or to fluoropyrimidine, irinotecan and oxaliplatin. (2009) (12)
- Significance of biological markers for predicting prognosis and selecting chemotherapy regimens of advanced gastric cancer patients between continuous infusion of 5-FU and a combination of 5-FU and cisplatin. (2007) (12)
- Modified FOLFOX-6 therapy for heavily pretreated advanced gastric cancer refractory to fluorouracil, irinotecan, cisplatin and taxanes: a retrospective study. (2012) (12)
- A retrospective study of second-line chemotherapy for unresectable or recurrent squamous cell carcinoma of the esophagus refractory to chemotherapy with 5-fluorouracil plus platinum (2008) (12)
- A phase II study of S-1 in patients with metastatic pancreatic cancer (2005) (12)
- Phase II study of sequential high-dose methotrexate and fluorouracil combined with doxorubicin as a neoadjuvant chemotherapy for scirrhous gastric cancer (2001) (12)
- Survival prolongation after treatment failure in patients with advanced gastric cancer (AGC): Results from combined analysis of JCOG9205 and JCOG9912. (2010) (11)
- S-1 monotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck after progression on platinum-based chemotherapy. (2011) (11)
- The effect of CYP2C19 polymorphism on the tolerability of ARQ 197: Results from phase I trial in Japanese patients with metastatic solid tumors. (2011) (11)
- JAVELIN Gastric 100: Phase 3 trial of avelumab (anti-PD-L1) maintenance therapy versus continuation of first-line chemotherapy in patients with advanced gastric or gastroesophageal junction cancer (GC/GEJC). (2018) (11)
- A phase III study of nivolumab (nivo) in previously treated advanced gastric or gastric esophageal junction (G/GEJ) cancer (ATTRACTION-2): Two-years update data. (2018) (11)
- Fluoropyrimidine with or without platinum as first-line chemotherapy in patients with advanced gastric cancer and severe peritoneal metastasis: a multicenter retrospective study (2019) (11)
- Features of Gemcitabine-Related Severe Pulmonary Toxicity: Patients With Pancreatic or Biliary Tract Cancer (2009) (11)
- Palliation of dysphagia in metastatic oesogastric cancers: An international multidisciplinary position. (2020) (11)
- Trastuzumab deruxtecan for the treatment of HER2-positive advanced gastric cancer: a clinical perspective (2021) (11)
- Multicenter phase II study of RAD001 for previously treated metastatic gastric cancer (MGC): Preliminary results (2008) (11)
- A phase II study of doxifluridine in elderly patients with advanced gastric cancer: the Japan Clinical Oncology Group Study (JCOG 9410). (2002) (11)
- Phase I study of sunitinib plus S-1 and cisplatin in Japanese patients with advanced or metastatic gastric cancer (2013) (11)
- A phase III study of nivolumab (Nivo) in previously treated advanced gastric or gastric esophageal junction (G/GEJ) cancer (ATTRACTION-2): Three-year update data. (2020) (11)
- Amrubicin in patients with platinum-refractory metastatic neuroendocrine carcinoma and mixed adenoneuroendocrine carcinoma of the gastrointestinal tract (2016) (11)
- Avelumab (MSB0010718C; anti-PD-L1) + best supportive care (BSC) vs BSC ± chemotherapy as third-line treatment for patients with unresectable, recurrent, or metastatic gastric cancer: The phase 3 JAVELIN Gastric 300 trial. (2016) (10)
- Phase II study of lenvatinib for metastatic colorectal cancer refractory to standard chemotherapy: the LEMON study (NCCH1503) (2020) (10)
- Clinical outcomes of locally advanced esophageal neuroendocrine carcinoma treated with chemoradiotherapy (2019) (10)
- Type of second primary malignancy after achieving complete response by definitive chemoradiation therapy in patients with esophageal squamous cell carcinoma (2018) (10)
- Treatment decision making in pancreatic adenocarcinoma: multidisciplinary team discussion with multidetector-row computed tomography. (2008) (10)
- Small cell carcinoma of the esophagus responding to fourth-line chemotherapy with weekly paclitaxel (2005) (10)
- Randomized phase III study of etoposide plus cisplatin versus irinotecan plus cisplatin in advanced neuroendocrine carcinoma of the digestive system: A Japan Clinical Oncology Group study (JCOG1213). (2015) (10)
- A Phase II study of preoperative chemotherapy with docetaxel, oxaliplatin and S-1 in gastric cancer with extensive lymph node metastasis (JCOG1704). (2020) (10)
- Imaging peritoneal metastasis of gastric cancer with 18F-fluorothymidine positron emission tomography/computed tomography: a proof-of-concept study. (2018) (10)
- Identification of a FGFR3-TACC3 fusion in esophageal cancer. (2016) (9)
- 671PInterim safety and clinical activity of nivolumab (Nivo) in combination with S-1/capecitabine plus oxaliplatin in patients (pts) with previously untreated unresectable advanced or recurrent gastric/gastroesophageal junction (G/GEJ) cancer: part 1 study of ATTRACTION-04 (ONO-4538-37) (2017) (9)
- Phase I study of highly selective inhibitor of VEGFR tyrosine kinase, tivozanib, in Japanese patients with solid tumors (2013) (9)
- Human equilibrative nucleoside transporter‐1 expression is a predictor in patients with resected pancreatic cancer treated with adjuvant S‐1 chemotherapy (2019) (9)
- Impact of baseline sum of longest diameter in target lesions by RECIST on survival of patients with metastatic colorectal cancer. (2008) (9)
- S-1 and Oxaliplatin Versus Tegafur-uracil and Leucovorin as Postoperative Adjuvant Chemotherapy in Patients With High-risk Stage III Colon Cancer (ACTS-CC 02): A Randomized, Open-label, Multicenter, Phase III Superiority Trial. (2019) (9)
- Active salvage chemotherapy versus best supportive care for patients with recurrent or metastatic squamous cell carcinoma of the esophagus refractory or intolerable to fluorouracil, platinum, and taxane (2016) (9)
- Pharmacokinetic analysis of capecitabine and cisplatin in combination with trastuzumab in Japanese patients with advanced HER2-positive gastric cancer (2012) (9)
- The peripheral immune status of granulocytic myeloid-derived suppressor cells correlates the survival in advanced gastric cancer patients receiving cisplatin-based chemotherapy (2017) (9)
- CD11b+CTLA4+ myeloid cells are a key driver of tumor evasion in colorectal cancer (2021) (9)
- Phase I/II study of oxaliplatin with weekly bolus fluorouracil and high-dose leucovorin (ROX) as first-line therapy for patients with colorectal cancer. (2006) (9)
- Olaparib plus paclitaxel sensitivity in biomarker subgroups of gastric cancer. (2018) (8)
- Retrospective comparison of nab-paclitaxel plus ramucirumab and paclitaxel plus ramucirumab as second-line treatment for advanced gastric cancer focusing on peritoneal metastasis (2019) (8)
- Development of an S-1 dosage formula based on renal function by a prospective pharmacokinetic study (2015) (8)
- Safety and efficacy of cell-free and concentrated ascites reinfusion therapy (CART) in gastrointestinal cancer patients with massive ascites treated with systemic chemotherapy (2020) (8)
- Exploration of time points and cut-off values for early tumour shrinkage to predict survival outcomes of patients with metastatic colorectal cancer treated with first-line chemotherapy using a biexponential model for change in tumour size (2017) (8)
- Preplanned initial safety analysis of ACTS-CC 02 trial: A large randomized phase III trial of SOX versus UFT/LV as adjuvant chemotherapy for high-risk stage III colon cancer. (2012) (8)
- Expression of Integrin α3 in Gastric and Colorectal Cancers: Its Relation to Wall Contraction and Mode of Invasion (1995) (8)
- Su1366 A NON-RANDOMIZED SINGLE-ARM CONFIRMATORY TRIAL OF ENDOSCOPIC SUBMUCOSAL DISSECTION TO EXPAND ITS INDICATION FOR EARLY GASTRIC CANCER OF UNDIFFERENTIATED TYPE: JAPAN CLINICAL ONCOLOGY GROUP STUDY (JCOG1009/1010) (2019) (8)
- Efficacy and safety of pemetrexed plus cisplatin as first-line chemotherapy in advanced malignant peritoneal mesothelioma. (2019) (8)
- Effectiveness of Etoposide and Cisplatin vs Irinotecan and Cisplatin Therapy for Patients With Advanced Neuroendocrine Carcinoma of the Digestive System (2022) (8)
- Placebo-controlled phase III study comparing dexamethasone on day 1 to on day 1-3 with NK1 receptor antagonist and palonosetoron in high emetogenic chemotherapy. (2016) (8)
- Impact of COVID-19 on gastric cancer treatment in Japanese high-volume centers: a JCOG stomach cancer study group survey (2021) (8)
- Clinical Outcomes of Resectable Esophageal Cancer with Supraclavicular Lymph Node Metastases Treated with Curative Intent. (2017) (7)
- Japan Society of Clinical Oncology Clinical Practice Guidelines 2017 for fertility preservation in childhood, adolescent, and young adult cancer patients: part 1 (2022) (7)
- Biomarker study for trastuzumab continuation beyond progression in a randomized phase II trial of weekly paclitaxel±trastuzumab in patients with HER2-positive advanced gastric or gastro-esophageal junction cancer refractory to trastuzumab combined with fluoropyrimidine and platinum (WJOG7112G). (2018) (7)
- Phase III trial of a 3-weekly versus 5-weekly schedule of S-1 plus cisplatin (SP) combination chemotherapy for first-line treatment of advanced gastric cancer (AGC): SOS study. (2013) (7)
- Impact of preoperative chemotherapy as initial treatment for advanced gastric cancer with peritoneal metastasis limited to positive peritoneal lavage cytology (CY1) or localized peritoneal metastasis (P1a): a multi-institutional retrospective study (2020) (7)
- Instrumental evaluation sensitively detects subclinical skin changes by the epidermal growth factor receptor inhibitors and risk factors for severe acneiform eruption (2018) (7)
- 626PDA randomized phase III trial comparing 4 courses and 8 courses of S-1 adjuvant chemotherapy for p-stage II gastric cancer: JCOG1104 (OPAS-1) (2017) (7)
- A multicenter phase II of S-1 in gemcitabine-refractory biliary tract cancer. (2010) (7)
- Health-related quality of life in a randomised phase III study of gemcitabine plus S-1, S-1 alone and gemcitabine alone for locally advanced or metastatic pancreatic cancer: GEST study (2017) (7)
- Five-year survivor with liver metastasis from gastric cancer successfully treated with systemic chemotherapy (2000) (7)
- Gastric mucosal injury and hemorrhage after definitive chemoradiotherapy for locally advanced esophageal cancer (2019) (7)
- Retrospective study of hyponatremia in gastric cancer patients treated with a combination chemotherapy of 5-fluorouracil and cisplatin: a possible warning sign of severe hematological toxicities? (2001) (7)
- First-line chemotherapy with S-1 alone or S-1 plus cisplatin for elderly patients with advanced gastric cancer: a multicenter propensity score matched study (2018) (7)
- Excessive watering eyes in gastric cancer patients receiving S-1 chemotherapy (2016) (7)
- Randomized phase II study of panitumumab (Pmab) + irinotecan (CPT-11) versus cetuximab (Cmab) + CPT-11 in patients (pts) with KRAS wild-type (WT) metastatic colorectal cancer (mCRC) after fluoropyrimidine (FU), CPT-11, and oxaliplatin (L-OHP) failure: WJOG6510G. (2017) (7)
- Phase I dose escalation and pharmacokinetics study of intravenous aflibercept plus irinotecan, 5-fluorouracil, and folinic acid (FOLFIRI) in patients with metastatic colorectal cancer. (2011) (7)
- An intergroup phase III trial of ramucirumab plus irinotecan in third or more line beyond progression after ramucirumab for advanced gastric cancer (RINDBeRG trial). (2018) (7)
- Planned Safety Analysis of the ACTS‐CC 02 Trial: A Randomized Phase III Trial of S‐1 With Oxaliplatin Versus Tegafur and Uracil With Leucovorin as Adjuvant Chemotherapy for High‐Risk Stage III Colon Cancer (2017) (7)
- Macroscopic typing with wall stricture sign may reflect tumor behaviors of advanced colorectal cancers (2001) (7)
- Long-term outcomes of patients with recurrent squamous cell carcinoma of the esophagus undergoing salvage endoscopic resection after definitive chemoradiotherapy (2020) (7)
- Prognostic impact of immunohistopathologic features in definitive radiation therapy for nasopharyngeal cancer patients (2019) (6)
- [Salvage operation for esophageal cancer after radical chemoradiotherapy]. (2002) (6)
- Questionnaire survey on adjuvant chemotherapy for elderly patients after gastrectomy indicates their vulnelabilities (2018) (6)
- Updated survival results of the randomized phase II study of S-1, oral leucovorin, and oxaliplatin combination therapy (SOL) versus mFOLFOX6 in patients with untreated metastatic colorectal cancer (mCRC). (2012) (6)
- A phase I trial of 5-fluorouracil with cisplatin and concurrent standard-dose radiotherapy in Japanese patients with stage II/III esophageal cancer. (2008) (6)
- Noninferiority of S-1 to UFT/LV as adjuvant chemotherapy for stage III colon cancer: A randomized phase III trial (ACTS-CC). (2013) (6)
- Perspectives for personalization in chemotherapy of advanced gastric cancer. (2010) (6)
- Activity of S-1 in advanced or recurrent gastric cancer patients after failure of prior chemotherapy, including irinotecan + cisplatin or fluorouracil (except S-1). (2009) (6)
- A multicenter phase II study of gemcitabine and S-1 combination therapy (GS therapy) in patients with metastatic pancreatic cancer (2007) (6)
- 6118 POSTER Randomized Phase II Study of S-1, Oral Leucovorin, and Oxaliplatin Combination Therapy (SOL) Versus MFOLFOX6 in Patients With Untreated Metastatic Colorectal Cancer (mCRC) (2011) (6)
- A phase III trial to confirm modified S-1 adjuvant chemotherapy for pathological stage II/III vulnerable elderly gastric cancer patients who underwent gastric resection (JCOG1507, BIRDIE). (2018) (6)
- Phase I study of sunitinib plus modified FOLFOX6 in Japanese patients with treatment-naive colorectal cancer. (2012) (6)
- Randomised phase II study of panitumumab plus irinotecan versus cetuximab plus irinotecan in patients with KRAS wild-type metastatic colorectal cancer refractory to fluoropyrimidine, irinotecan and oxaliplatin (WJOG 6510G). (2020) (6)
- Chemoradiotherapy for Local Recurrence of Rectal Cancer: A Single Center Study of 18 Patients (2019) (6)
- Past and present achievements, and future direction of the Gastrointestinal Oncology Study Group (GIOSG), a Division of Japan Clinical Oncology Group (JCOG). (2011) (6)
- Clinicopathological features and outcomes of gastric cancer patients with pulmonary lymphangitis carcinomatosa. (2014) (6)
- A phase II study of chemoradiotherapy in patients with stage II, III esophageal squamous cell carcinoma (ESCC): (JCOG 9906) (2007) (6)
- Exploration of predictors of benefit from nivolumab monotherapy for patients with pretreated advanced gastric and gastroesophageal junction cancer: post hoc subanalysis from the ATTRACTION-2 study (2021) (6)
- Lymphocyte-to-C-Reactive Protein Ratio Is the Most Sensitive Inflammation-Based Prognostic Score in Patients With Unresectable Metastatic Colorectal Cancer (2021) (6)
- The effect of CYP 2 C 19 polymorphism on the safety , tolerability , and pharmacokinetics of tivantinib ( ARQ 197 ) : results from a phase I trial in advanced solid tumors (2013) (6)
- Efficacy and safety of taxane monotherapy in advanced gastric cancer refractory to triplet chemotherapy with docetaxel, cisplatin, and S-1: a multicenter retrospective study (2017) (6)
- The peripheral immune status of granulocytic myeloid-derived suppressor cells correlates the survival in advanced gastric cancer patients receiving cisplatin-based chemotherapy. (2017) (6)
- Gastrointestinal tumors, non-colorectal (2012) (6)
- Heterogeneity of Tumor Sizes in Multiple Pulmonary Metastases of Colorectal Cancer as a Prognostic Factor. (2017) (5)
- Clinicopathological features and pathological evaluation of preoperative treatment of patients with resectable esophageal carcinosarcoma (2017) (5)
- Molecular prognostic markers in advanced gastric cancer: Correlative study in the Japan Clinical Oncology Group trial JCOG9912. (2011) (5)
- A phase I study of the chimeric monoclonal anti-epidermal growth factor receptor (EGFR) antibody cetuximab as a single agent in subjects from Japan with advanced solid tumors: Safety, pharmacokinetics (PK) (2005) (5)
- Japan Society of Clinical Oncology Clinical Practice Guidelines 2017 for fertility preservation in childhood, adolescent, and young adult cancer patients: part 2 (2022) (5)
- T-ACT (WJOG7112G): A randomized phase II study of weekly paclitaxel ± trastuzumab in patients with HER2-positive advanced gastric or gastro-esophageal junction cancer refractory to trastuzumab combined with fluoropyrimidine and platinum. (2017) (5)
- Multicenter, phase II study of trastuzumab and paclitaxel to treat HER2-positive, metastatic gastric cancer patients naive to trastuzumab (JFMC45-1102). (2013) (5)
- Prospective Evaluation of the Optimal Duration of Bed Rest After Vascular Interventions Using a 3-French Introducer Sheath (2015) (5)
- Induction chemotherapy with docetaxel, cisplatin and fluorouracil followed by concurrent chemoradiotherapy for unresectable sinonasal undifferentiated carcinoma: Two cases of report (2019) (5)
- A phase II study of S-1, oxaliplatin, oral leucovorin, and bevacizumab combination therapy (SOLA) in patients with unresectable metastatic colorectal cancer (2015) (5)
- Diagnosis of invasion depth in resectable advanced gastric cancer for neoadjuvant chemotherapy: An exploratory analysis of Japan clinical oncology group study: JCOG1302A. (2020) (5)
- Surgical outcome for pulmonary metastasis of colorectal cancer in the modern chemotherapy era: Results of a retrospective Japanese multicenter study. (2014) (5)
- Treatment Pattern for Advanced Gastric Cancer in Japan and Factors Associated with Sequential Treatment: A Retrospective Administrative Claims Database Study (2021) (5)
- Impact of peripheral neuropathy induced by platinum in first-line chemotherapy on second-line chemotherapy with paclitaxel for advanced gastric cancer (2019) (5)
- FINAL RESULTS OF A PHASE II STUDY OF S-1 IN PATIENTS WITH METASTATIC PANCREATIC CANCER (2006) (5)
- CD11b+DIP2A+LAG3+ cells facilitate immune dysfunction in colorectal cancer. (2021) (4)
- Safety and Efficacy of Proton-Beam Radiation Therapy for Patients with Locally Recurrent rectal Cancer (2012) (4)
- Temporal dynamics from phosphoproteomics using endoscopic biopsy specimens provides new therapeutic targets in stage IV gastric cancer (2022) (4)
- Phase 1b study of andecaliximab (GS-5745, ADX) as monotherapy and in combination with nivolumab (nivo) in Japanese subjects with gastric or GEJ adenocarcinoma. (2019) (4)
- Treatment of opioid-induced constipation with naldemedine in patients with cancer: onset of action in a randomized phase 3 trial (2016) (4)
- Comparison of involved field radiotherapy and elective nodal irradiation in combination with concurrent chemotherapy for T1bN0M0 esophageal cancer (2020) (4)
- Regional differences in patient (pt) characteristics of AVAGAST: An exploratory comparison in chemotherapy plus placebo (PL) arm between Japanese (JPN) and the rest of the world (ROW) pts. (2012) (4)
- Selection of Second‐line Anti‐angiogenic Agents After Failure of Bevacizumab‐containing First‐line Chemotherapy in Metastatic Colorectal Cancer (2018) (4)
- Retrospective observational study of salvage line ramucirumab monotherapy for patients with advanced gastric cancer (2020) (4)
- Second-line chemotherapy after early disease progression during first-line chemotherapy containing bevacizumab for patients with metastatic colorectal cancer (2021) (4)
- Phase I clinical and pharmacokinetic study of S-1 plus oral leucovorin in patients with metastatic colorectal cancer (2016) (4)
- Phase I study of nimotuzumab, a humanized anti-epidermal growth factor receptor (EGFR) IgG1 monoclonal antibody in patients with solid tumors in Japan. (2009) (4)
- Comparison of combination chemotherapy with irinotecan and cisplatin regimen administered every 2 or 4 weeks in pretreated patients with unresectable or recurrent gastric cancer: retrospective analysis (2010) (4)
- Study protocol for a multi-institutional randomized phase III study comparing combined everolimus plus lanreotide therapy and everolimus monotherapy in patients with unresectable or recurrent gastroenteropancreatic neuroendocrine tumors; Japan Clinical Oncology Group Study JCOG1901 (STARTER-NET stud (2020) (4)
- 6590 A phase II study of erlotinib plus gemcitabine in Japanese patients with unresectable pancreatic cancer (2009) (4)
- aCGH Analysis of Predictive Biomarkers for Response to Bevacizumab plus Oxaliplatin- or Irinotecan-Based Chemotherapy in Patients with Metastatic Colorectal Cancer. (2018) (4)
- Plasma ICAM-1 (pICAM-1) and plasma IL-8 (pIL-8) level as biomarker of metastatic colorectal cancer patients (mCRC) treated with mFOLFOX6/XELOX plus bevacizumab (BV) (WJOG7612GTR). (2018) (4)
- A prospective, randomized, double-blinded, placebo-controlled, phase III study to evaluate the efficacy and safety of apatinib plus best supportive care (BSC) compared to placebo plus BSC in patients with advanced or metastatic gastric cancer: The ANGEL study. (2017) (4)
- Results of a retrospective analysis of gemcitabine as a second-line treatment after chemoradiotherapy and maintenance chemotherapy using 5-fluorouracil in patients with locally advanced pancreatic cancer (2008) (4)
- Time-dependent discrepancies between physician-assessed and patient-reported oxaliplatin-induced peripheral neuropathy in patients with metastatic colorectal cancer who received mFOLFOX6 plus bevacizumab: a post hoc analysis (WJOG4407GSS2) (2020) (4)
- S-1 Monotherapy After Failure of Platinum Plus 5-Fluorouracil Chemotherapy in Recurrent or Metastatic Esophageal Carcinoma (2019) (4)
- A phase III study of TAS-118 plus oxaliplatin versus S-1 plus cisplatin as first-line chemotherapy in patients with advanced gastric cancer (SOLAR study). (2019) (4)
- Advanced esophageal cancer with esophago-bronchial fistula successfully treated by chemoradiation therapy with additional endoscopic resection: a case report. (2002) (4)
- Response of the primary lesion in gastric cancer to chemotherapeutic trials (1998) (4)
- A Phase II Study of Irinotecan in Combination with 120-h Infusion of 5-Fluorouracil in Patients with Metastatic Colorectal Carcinoma : Japan Clinical Oncology Group Study ( JCOG 9703 ) (2002) (3)
- The role of the outpatient clinic in chemotherapy for patients with unresectable or recurrent gastric cancer. (2007) (3)
- Phase 3 study to evaluate the efficacy and safety of naldemedine for the treatment of opioid-induced constipation (OIC) in cancer patients. (2016) (3)
- Phase II/III clinical trial with VEGFR2-epitope peptide and gemcitabine for patients with locally advanced, metastatic, or unresectable pancreatic cancer: Pegasus-PC study. (2013) (3)
- Evaluation of efficacy of nivolumab by baseline factors from ATTRACTION-2. (2019) (3)
- Predictability of antitumor efficacy of cetuximab plus irinotecan based on skin rash severity according to observation period in patients with metastatic colorectal cancer following failure of fluorouracil, irinotecan and oxaliplatin. (2015) (3)
- Endoscopic mucosal resection for early adenocarcinoma arising in Barrett's esophagus (2001) (3)
- A phase II trial of 5-weekly S-1 plus cisplatin (CDDP) combination with trastuzumab (Tmab) for HER2-positive advanced gastric or esophagogastric junction (EGJ) cancer: WJOG7212G (T-SPACE) study. (2015) (3)
- [Histological complete response in a case of advanced gastric cancer treated by neo-adjuvant chemotherapy with S-1/CDDP]. (2010) (3)
- Trastuzumab Emtansine (T-DM1) Plus S-1 in Patients with Trastuzumab-Pretreated HER2-Positive Advanced or Metastatic Breast Cancer: A Phase Ib Study (2019) (3)
- Study protocol for NCCH1908 (UPFRONT-trial): a prospective clinical trial to evaluate the feasibility and utility of comprehensive genomic profiling prior to the initial systemic treatment in advanced solid tumour patients. (2021) (3)
- Tolerability and safety of oral neratinib (HKI-272) in Japanese patients with advanced solid tumors. (2009) (3)
- Consensus Statement on Mandatory Measurements for Pancreatic Cancer Trials for Patients With Resectable or Borderline Resectable Disease (COMM-PACT-RB): A Systematic Review and Delphi Consensus Statement. (2022) (3)
- 3542 POSTER Preliminary results from a phase II study of sunitinib as second-line treatment for advanced gastric cancer (2007) (3)
- Assessment of hyperprogression versus the natural course of disease development with nivolumab with or without ipilimumab versus placebo in phase III, randomized, controlled trials (2022) (3)
- Surgical and perioperative treatment strategy for resectable esophagogastric junction cancer. (2022) (3)
- JCOG trials of systemic chemotherapy for unresectable or recurrent gastric cancer (2009) (3)
- Hyperprogressive disease during nivolumab chemotherapy in metastatic gastric cancer: Multicenter retrospective study in Japan. (2020) (3)
- Subgroup analysis of JCOG0501 phase III study to confirm superiority of additional neoadjuvant chemotherapy with S-1 plus cisplatin to D2 gastrectomy with S-1 adjuvant chemotherapy for resectable type IV or large type III gastric cancer. (2019) (3)
- Verrucous carcinoma of the esophagus completely resected by endoscopy. (2000) (3)
- Prognostic factors for PFS in patients with advanced gastric cancer: Using the data from JCOG9912 study. (2011) (3)
- Efficacy and safety of trastuzumab (T-mab) and paclitaxel for T-mab naïve patients with HER2 positive previously treated metastatic gastric cancer (JFMC45-1102). (2013) (3)
- Quality of life (QOL) evaluation within a randomized phase III study of gemcitabine plus S-1 (GS) versus S-1 versus gemcitabine (GEM) in unresectable, advanced pancreatic cancer (PC) in Japan and Taiwan: GEST study. (2011) (3)
- Current status and problems in development of molecular target agents for gastrointestinal malignancy in Japan. (2010) (3)
- Phase I study of docetaxel, cisplatin and S-1 in patients with advanced gastric cancer. (2010) (3)
- Two cases of rupture of esophagogastric varices during the course of oxaliplatin-based chemotherapy for colorectal cancer. (2014) (3)
- Final results of phase II study of S-1, oral leucovorin, oxaliplatin, and bevacizumab combination therapy (SOL+BV; SOLA) in metastatic colorectal cancer (mCRC). (2014) (3)
- Prospective evaluation and refinement of an S‐1 dosage formula based on renal function for clinical application (2020) (3)
- Safety and tolerability of andecaliximab as monotherapy and in combination with an anti-PD-1 antibody in Japanese patients with gastric or gastroesophageal junction adenocarcinoma: a phase 1b study (2022) (3)
- Inter-institutional heterogeneity in outcomes of chemotherapy for metastatic gastric cancer: correlative study in the JCOG9912 phase III trial (2016) (3)
- Comparison between fluorescent images of gastric cancer with an endoscopic autofluorescence imaging system and the histological findings (1998) (2)
- Risk factors for the continuation of S-1 adjuvant chemotherapy for gastric cancer analyzed from the JCOG1104 phase III trial. (2021) (2)
- Phase I study of AMG 479, a fully human monoclonal antibody against the type 1 insulin-like growth factor receptor (IGF-1R), in Japanese patients (pts) with advanced solid tumors. (2011) (2)
- Relationship between cervical esophageal squamous cell carcinoma and human papilloma virus infection and gene mutations (2020) (2)
- Prognostic factors in Japanese patients with advanced gastric cancer using the data from JCOG9912 study. (2011) (2)
- Response to Y. Sasaki et al.: Is repeating FOLFIRINOX in the original dosage and treatment schedule tolerable in Japanese patients with pancreatic cancer? (2015) (2)
- Second gastric cancer after curative endoscopic resection of differentiated-type early gastric cancer: post-hoc analysis of single-arm confirmatory trial. (2021) (2)
- Study protocol of a single-arm phase 2 study evaluating the preventive effect of topical hydrocortisone for capecitabine-induced hand-foot syndrome in colorectal cancer patients receiving adjuvant chemotherapy with capecitabine plus oxaliplatin (T-CRACC study) (2022) (2)
- Association of UGT1A1 gene polymorphism with the safety and efficacy of irinotecan monotherapy for advanced gastric cancer. (2017) (2)
- A randomized multicenter phase II study of FOLFIRI plus either panitumumab (Pmab) or bevacizumab (Bmab) as second-line treatment for wild-type KRAS exon 2 metastatic colorectal cancer (mCRC) with exploratory biomarker analysis by liquid biopsy: WJOG6210G. (2016) (2)
- Loss of body weight during neoadjuvant chemotherapy with docetaxel, cisplatin, and fluorouracil as predictive of poor survival of patients with esophageal squamous cell carcinoma. (2020) (2)
- PLS. plenary session (2012) (2)
- Nivolumab safety profile in Asian and Western patients with chemotherapy-refractory (CTx-R) advanced gastric/gastroesophageal junction (adv G/GEJ) cancer from the ATTRACTION-2 and CheckMate-032 trials. (2018) (2)
- Prediction of tissue-of-origin of early stage cancers using serum miRNomes (2022) (2)
- Retrospective study of nivolumab monotherapy for advanced esophageal squamous cell carcinoma. (2021) (2)
- [Molecular target therapy and chemotherapy for advanced colorectal cancer]. (2008) (2)
- Feasibility of mFOLFOX6 as the adjuvant treatment after curative resection of metastases from colorectal cancer in Japanese patients (2013) (2)
- Phase I dose-escalation study of the safety, tolerability, and pharmacokinetics of aflibercept in combination with S-1 in Japanese patients with advanced solid malignancies (2020) (2)
- [Phase I / II study of XELOX plus bevacizumab in Japanese patients with metastatic colorectal cancer(JO19380)]. (2011) (2)
- A phase II study of lenvatinib in patients with metastatic colorectal cancer refractory to standard chemotherapy: LEMON study (NCCH1503). (2019) (2)
- Phase I/II study of S-1/LV plus oxaliplatin (SOL) for untreated metastatic colorectal cancer: Preliminary report of the phase I part (2008) (2)
- Real‐world emetic risk of chemotherapy and the corresponding antiemetic therapy in Japan: A study based on a nationwide database (2021) (2)
- Real-world safety and effectiveness of nivolumab in Japanese patients with unresectable advanced or recurrent gastric/gastroesophageal junction cancer that has progressed after chemotherapy: a postmarketing surveillance study (2021) (2)
- Indications for fertility preservation not included in the 2017 Japan Society of Clinical Oncology Guideline for Fertility Preservation in Pediatric, Adolescent, and Young Adult Patients treated with gonadal toxicity, including benign diseases (2021) (2)
- Efficacy and safety result of trastuzumab (T-mab) and paclitaxel for T-mab naive patients with HER2-positive previously treated advanced or recurrent gastric cancer (JFMC45-1102): Final report. (2014) (2)
- A phase 1b study of andecaliximab in combination with S-1 plus platinum in Japanese patients with gastric adenocarcinoma (2022) (2)
- The impact of early tumor shrinkage on survival in WJOG4407G trial, a randomized phase III trial of mFOLFOX6 plus bevacizumab versus FOLFIRI plus bevacizumab in first-line treatment for metastatic colorectal cancer. (2015) (2)
- A randomized phase II trial of systemic chemotherapy with or without trastuzumab followed by surgery in HER2 positive advanced gastric or esophagogastric junction adenocarcinoma with extensive lymph node metastasis: Japan Clinical Oncology Group study JCOG1301C (Trigger study). (2016) (2)
- Randomized phase II study of panitumumab (Pmab) plus irinotecan (CPT-11) versus cetuximab (Cmab) plus CPT-11 in patients with KRAS wild-type (WT) metastatic colorectal cancer (mCRC) following treatment with fluoropyrimidine, CPT-11, and oxaliplatin (L-OHP) chemotherapy: WJOG6510G. (2014) (2)
- 625PRANDOMIZED PHASE II STUDY OF S-1 PLUS ORAL LEUCOVORIN (SL) VERSUS SL PLUS OXALIPLATIN (SOL) VERSUS S-1 PLUS CISPLATIN (SP) IN PATIENTS WITH ADVANCED GASTRIC CANCER (AGC):UPDATED OVERALL SURVIVAL DATA. (2014) (2)
- Efficacy of second-line treatment and prognostic factors in patients with advanced malignant peritoneal mesothelioma: a retrospective study (2021) (2)
- Posttherapy topographical nodal status, ypN-site, predicts survival of patients who received neoadjuvant chemotherapy followed by curative surgical resection for non-type 4 locally advanced gastric cancer: supplementary analysis of JCOG1004-A (2020) (2)
- 9413 Phase II trial of adjuvant imatinib mesylate after resection of localized, primary high risk gastrointestinal stromal tumour (GIST) in Japan (2009) (2)
- Esophageal Metastasis from Rectal Cancer Successfully Treated with Fluorouracil-Based Chemotherapy with Bevacizumab: A Case Report and Review of the Literature (2017) (2)
- Topical corticosteroid therapy for facial acneiform eruption due to EGFR inhibitors in metastatic colorectal cancer patients: a randomized controlled trial comparing starting with a very strong or a weak topical corticosteroid (FAEISS study, NCCH1512, colorectal part) (2021) (2)
- P1-5-18Re-introduction of taxane for patients with esophageal squamous cell carcinoma refractory to 5-FU, CDDP, and a taxane (2015) (2)
- [Chemotherapy-naïve advanced pancreatic cancer with multiple liver metastases successfully treated by S-1 monotherapy--a case report]. (2006) (2)
- Clinical outcomes of patients with G1/G2 neuroendocrine tumors arising from foregut or hindgut treated with somatostatin analogs: a retrospective study (2018) (2)
- [A guideline for antimetics use for patients with malignancies]. (2012) (2)
- TAS-118 (S-1 plus leucovorin) versus S-1 in gemcitabine-refractory advanced pancreatic cancer: A randomized, open-label, phase III trial (GRAPE trial). (2017) (2)
- Adverse effects of cell-free and concentrated ascites reinfusion therapy for malignant ascites: a single-institute experience (2020) (2)
- Retrospective analysis of the effects of systemic chemotherapy to the ovarian metastases from colorectal cancer. (2017) (1)
- Retrospective observational study of salvage line ramucirumab monotherapy (RAM) for patients (pts) with unresectable advanced gastric cancer (AGC) which was refractory to fluoropyrimidine and taxanes. (2018) (1)
- PS02.133: THE EFFICACY AND SAFETY OF S-1 MONOTHERAPY FOR RECURRENT OR METASTATIC ESOPHAGEAL SQUAMOUS CELL CARCINOMA REFRACTORY OR INTOLERABLE TO PLATINUM PLUS 5-FU (2018) (1)
- Evaluation of α-1-acid glycoprotein as a prognostic factor of survival in patients with stage II-III esophageal carcinoma treated with neoadjuvant docetaxel, cisplatin, and fluorouracil chemotherapy followed by surgery. (2015) (1)
- Abstract C6: Phase 1 study of conatumumab (AMG 655), a proapoptotic death receptor‐5 agonist antibody, in Japanese patients with advanced solid tumors (2009) (1)
- Correlation of tumor mutation with efficacy in patients with gastric cancer who received nivolumab and ramucirumab combination therapy. (2020) (1)
- Protocol digest of a phase III trial to evaluate the efficacy of preoperative chemotherapy with S-1 plus oxaliplatin followed by D2 gastrectomy with postoperative S-1 in locally advanced gastric cancer: Japan Clinical Oncology Group study JCOG1509 (NAGISA Trial) (2022) (1)
- A phase I study of the combination of panitumumab and bevacizumab in KRAS wild-type colorectal cancer patients previously treated with fluoropyrimidine, oxaliplatin, irinotecan and bevacizumab (2016) (1)
- A randomized phase III trial of S-1/oxaliplatin (SOX) versus UFT/leucovorin as adjuvant chemotherapy for high-risk stage III colon cancer: The ACTS-CC 02 trial. (2019) (1)
- 2168 Predictive biomarker analysis of early tumor shrinkage induced by FOLFIRI+Bev for patients with metastatic colorectal cancer in WJOG4407G study (2015) (1)
- Immune status at pre-treatment impacts on progression-free survival of metastatic colorectal cancer patients treated with first-line chemotherapy (2015) (1)
- Mismatch-repair-deficient metastatic pancreatic ductal adenocarcinoma with a germline PALB 2 mutation : unusual genetics , unusual clinical course (2017) (1)
- Pretreatment risk factors for endoscopic noncurative resection of gastric cancers with undifferentiated‐type components (2022) (1)
- 5067 POSTER A Phase 1 Study of Neratinib in Combination With Vinorelbine in Japanese Patients With Advanced or Metastatic Solid Tumours (2011) (1)
- Safety and early efficacy results of a phase Ib study of nivolumab plus trastuzumab with S-1/capecitabine plus oxaliplatin for HER2-positive advanced gastric cancer (Ni-HIGH study). (2022) (1)
- Phase II study of oxaliplatin combined with S-1 (SOX) as first-line therapy for patients with advanced gastric cancer (AGC). (2009) (1)
- Phase I/II study of oral fluoropyrimidine S-1 plus oral Leucovorin as first-line treatment for metastatic colorectal cancer (2007) (1)
- Emerging treatment with systemic chemotherapy and targeted agents for biliary cancers. (2010) (1)
- The hyperprogressive disease during nivolumab treatment or irinotecan treatment in patients with advanced gastric cancer. (2019) (1)
- A phase III trial to confirm the superiority of S-1 adjuvant chemotherapy for vulnerable elderly patients with pathological stage II/III gastric cancer after curative resection: JCOG1507 (BIRDIE). (2018) (1)
- Impact of adding ramucirumab to paclitaxel in patients with advanced gastric cancer according to the level of ascites: A multicenter retrospective study. (2018) (1)
- Updated results of the GEST study: Randomized phase III study of gemcitabine plus S-1 (GS) versus S-1 versus gemcitabine (GEM) in unresectable advanced pancreatic cancer in Japan and Taiwan. (2012) (1)
- [Comparison of Response to Chemotherapy between Ovarian and Extraovarian Metastasis of Gastric Cancer]. (2017) (1)
- 422 POSTER A phase I study of oral panobinostat (LBH589) in Japanese patients with advanced solid tumours (2008) (1)
- Clinical factors associated with non-curative endoscopic submucosal dissection for the expanded indication of intestinal-type early gastric cancer: a post hoc analysis of a multi-institutional, single-arm, confirmatory trial (JCOG0607). (2022) (1)
- A phase II randomized, double-blind, placebo-controlled study to evaluate naldemedine for the treatment of opioid-induced constipation (OIC) in patients with cancer pain. (2015) (1)
- Psychological distress among healthcare providers in oncology during the COVID-19 pandemic in Japan: The mediating role of moral distress and resilience (2023) (1)
- Docetaxel Plus Cisplatin and S-1 versus Cisplatin and S-1 in Patients with Advanced Gastric Cancer (JCOG1013): An Open-Label, Randomised, Phase 3 Trial (2019) (1)
- Randomized phase II/III study of 5-fluorouracil/l-leucovorin versus 5-fluorouracil/l-leucovorin plus paclitaxel in gastric cancer with severe peritoneal metastasis (JCOG1108/WJOG7312G). (2019) (1)
- [Ⅲ. Chemotherapy for Gastric Cancer -Revised Points of the 6th Edition of Japanese Gastric Cancer Treatment Guidelines]. (2021) (1)
- Diagnosis of invasion depth in resectable advanced gastric cancer for neoadjuvant chemotherapy: An exploratory analysis of JCOG1302A. (2018) (1)
- Evaluation of clinical validity of an S-1 dosage formula based on renal function using data of the SPIRITS and the G-SOX trials (2022) (1)
- 6063 Phase I study of first-line sunitinib (SU) plus modified FOLFOX6 (mFOLFOX6) in Japanese patients (pts) with metastatic colorectal cancer (mCRC) (2009) (1)
- Randomized phase III trial to evaluate omentum preserving gastrectomy for patients with resectable advanced gastric cancer: JCOG1711 (ROAD-GC). (2020) (1)
- SPS-6WJOG6510G: Randomized phase II of Pmab + IRI vs Cmab + IRI for KRAS WT mCRC previously treated after FU, IRI, and L-OHP (2017) (1)
- Incidence and prognostic factors in severe drug-induced interstitial lung disease caused by antineoplastic drug therapy in the real world (2022) (1)
- A phase Ib study of nivolumab plus trastuzumab with S-1/capecitabine plus oxaliplatin for HER2-positive advanced gastric cancer (Ni-HIGH study): Safety evaluation. (2020) (1)
- Analysis of totally implantable venous access port systems (TIVAPS) related adverse events (AEs) in metastatic colorectal cancer (mCRC) patients treated with and without bevacizumab. (2013) (1)
- Predictive biomarker analysis of early tumor shrinkage induced by FOLFIRI+Bev for patients with metastatic colorectal cancer in WJOG4407G study. (2015) (1)
- Updated report of a randomized phase III trial comparing 4 and 8 courses of S-1 adjuvant chemotherapy for p-stage II gastric cancer: JCOG1104 (OPAS-1). (2018) (1)
- 6624 Treatment of metastatic poorly differenciated neuroendocrine carcinoma (PDNEC) with irinotacan plus cisplatin (2009) (1)
- Prognostic factors of brain metastases from colorectal cancer (2019) (1)
- Comparison of clinicopathological and genomic profiles in anal squamous cell carcinoma between Japanese and Caucasian cohorts (2023) (1)
- [The role of oral fluoropyrimidines in colorectal cancer treatment--a review]. (2010) (1)
- LAG3-related factors to predict response to nivolumab monotherapy in advanced gastric cancer (WJOG10417GTR study). (2023) (1)
- Risk Factors of Hand-foot Skin Reaction Caused by Regorafenib in Patients with Unresectable Advanced or Recurrent Colorectal Cancer (2015) (1)
- Factors associated with treatment duration from start of second-line ramucirumab plus paclitaxel or nab-PTX for advanced gastric cancer: real-world evidence from Japanese Claim Database. (2021) (1)
- Multicenter Retrospective Analysis of Systemic Chemotherapy for Advanced Poorly Differentiated Neuroendocrine Carcinoma of Digestive System (2012) (1)
- A phase Ib study of nivolumab plus trastuzumab with S-1/capecitabine plus oxaliplatin for HER2 positive advanced gastric cancer (Ni-HIGH study). (2019) (1)
- Planned safety analysis of the ACTS-CC 02 trial: A randomized phase III trial of S-1/oxaliplatin (SOX) versus UFT/LV as adjuvant chemotherapy for high-risk stage III colon cancer. (2016) (1)
- ARHGAP–RhoA signaling provokes homotypic adhesion-triggered cell death of metastasized diffuse-type gastric cancer (2022) (1)
- Panitumumab-Associated Drug-Induced Immune Thrombocytopenia in a Patient with Colorectal Cancer (2021) (1)
- Abstract B98: AUY922, a novel HSP90 inhibitor: Final results of a phase I dose escalation study in Japanese patients with advanced solid malignancies. (2011) (1)
- Prediction of the peritoneal recurrence via the macroscopic diagnosis of the serosal invasion in patients with gastric cancer: Supplementary analysis of JCOG0110. (2022) (1)
- Current status and problems of molecular target therapy for colorectal cancer. (2011) (1)
- The impact of pre-operative chemotherapy in patients with peritoneal lavage cytology positive or localized peritoneum metastasis for gastric cancer: A multicenter retrospective study. (2018) (1)
- Retrospective comparison of long-term outcomes in patients with stage II/III (UICC-TNM6th) esophageal squamous cell carcinoma treated with 60 Gy or 50.4 Gy of definitive chemoradiotherapy with fluorouracil and platinum. (2016) (1)
- Endoscopic evaluation of primary tumor response in patients with metastatic colorectal cancer treated by systemic chemotherapy (2013) (1)
- 699 A Non-Randomized Confirmatory Trial of Endoscopic Submucosal Dissection to Expand Its Indication for Early Gastric Cancer (Ct1a): The Japan Clinical Oncology Group Study (Jcog0607) (2016) (1)
- A model chemosensitivity test examining apoptosis in small specimens of gastric cancer (2000) (1)
- Serum microRNAs to predict the response to nivolumab in patients with esophageal squamous cell carcinoma. (2017) (1)
- S-1 as adjuvant chemotherapy for stage III colon cancer: Updated outcomes of ACTS-CC trial. (2015) (1)
- [Nivolumab Treatment for the Patients with Gastric Cancer-Present and Future]. (2019) (1)
- Oxaliplatin (L-OHP) in combination with 5-fluorouracil (5-FU)/l-leucovorin (l-LV) on modified Roswell Park regimen as first-line treatment of advanced colorectal cancer (ACRC): A phase I/II study (2004) (1)
- Clinical implication of using up both fluoropyrimidine (FU) and paclitaxel (PTX) in patients with severe peritoneal metastases (SPM) of gastric cancer (GC). (2021) (1)
- [The survey for anti-emetic guideline by using questioner]. (2015) (1)
- Efficacy and safety of taxane-monotherapy in advanced gastric cancer refractory to triplet chemotherapy with docetaxel, cisplatin, and S-1: A multicenter retrospective study. (2017) (1)
- Regorafenib as second-line therapy for imatinib-resistant gastrointestinal stromal tumor (GIST). (2020) (1)
- Impact of Oxaliplatin-Induced Neuropathy on Subsequent Paclitaxel for Advanced Gastric Cancer (2020) (1)
- [Molecular target for Her2 positive gastric cancer]. (2012) (1)
- A Phase I study of pevonedistat plus capecitabine plus oxaliplatin in patients with advanced gastric cancer refractory to platinum (NCCH-1811) (2021) (1)
- 428 POSTER A phase I dose-escalation study of TAS-102, a novel oral functional antitumor nucleoside, administered twice daily to Japanese patients (pts) with advanced solid tumors (2008) (1)
- Gastrointestinal tumors, colorectal (2012) (1)
- Validation of the JCOG prognostic index in advanced gastric cancer of the SPIRITS and G-SOX trials, using individual patient data. (2016) (1)
- Second-line chemotherapy with paclitaxel for elderly patients with advanced gastric cancer. (2016) (1)
- 394 POSTER Final results of a Phase I study of cediranib, a VEGFR signaling inhibitor, in Japanese patients with advanced solid tumors (2008) (1)
- Phase III randomised trial comparing 6 vs. 12-month of capecitabine as adjuvant chemotherapy for patients with stage III colon cancer: final results of the JFMC37-0801 study (2019) (1)
- The Differential Diagnosis of Malignant Lymphoma and Reactive Lymphoreticular Hyperplasia of the Stomach Using Endoscopic Ultrasonography (1994) (1)
- 259 Fibroblast growth factor 9 gene amplification can induce resistance to anti-EGFR therapy in colorectal cancer (2015) (0)
- A phase I study of combination of panitumumab and bevacizumab in KRAS wild-type colorectal cancer patients who were previously treated with fluoropyrimidine, oxaliplatin, irinotecan, and bevacizumab. (2016) (0)
- The impact of postoperative complications on survival outcomes in patients with cT3/4a gastric cancer. (2019) (0)
- Correction to: Incidence and prognostic factors in severe drug-induced interstitial lung disease caused by antineoplastic drug therapy in the real world (2022) (0)
- Imaging peritoneal metastasis of gastric cancer with PET/CT and the radiotracer 18F-fluorothymidine (18F-FLT):Proof-of-concept study. (2015) (0)
- P-100 A phase II study of first-line chemotherapy initiating FOLFIRI+cetuximab and switching to FOLFIRI+bevacizumab according to early tumor shrinkage at 8 weeks in RAS wild-type metastatic colorectal cancer: HYBRID trial (2021) (0)
- Abstract 3772: Comprehensive characterization of the phosphoproteome of gastric cancer from endoscopic biopsy specimens (2020) (0)
- Risks of severe adverse events of docetaxel, cisplatin, and 5-fluorouracil (DCF) combination chemotherapy of esophageal cancer. (2015) (0)
- Chemotherapy for Metastatic Gastric Cancer: Results from Clinical Trials in Asia (2004) (0)
- Evaluating the efficacy of post-operative chemotherapy after curative resection of stage IV gastric cancer with synchronous oligo metastasis: a multicenter retrospective study (2023) (0)
- Comparison of S-1 and S-1 plus cisplatin as post-operative chemotherapy for gastric carcinoma with peritoneal lavage cytology positive or localized peritoneum metastasis: A multicenter retrospective study. (2018) (0)
- PSY8-2 Search of biomarkers and creation of innovative methods required for precision medicine for gastric cancer (2021) (0)
- Acknowledgement of reviewers 2020 (2021) (0)
- A STUDY OF DIVERGENT MORPHOLOGY OF THE PANCREATIC DUCT BY COMPUTED TOMOGRAPHY UNDER ENDOSCOPIC RETROGRADE PANCREATOGRAPHY (1996) (0)
- ASO Author Reflections: What Is the Best Treatment for Gastric Cancer with Positive Peritoneal Lavage Cytology or Localized Peritoneum Metastasis? (2019) (0)
- Expression of B7-H3 (CD276) in surgically resected esophageal squamous cell carcinoma. (2018) (0)
- Retrospective analysis of systemic chemotherapy for unresectable advanced biliary tract cancer (2005) (0)
- Histopathological tumor regression or ypN: Which better predicts survival of patients who received neoadjuvant chemotherapy and surgery for non-type 4 locally advanced gastric cancer? (2018) (0)
- Altered mucosal immunity in HIV-positive colon adenoma: decreased CD4+ T cell infiltration is correlated with nadir but not current CD4+ T cell blood counts (2022) (0)
- P1-5-3The association between time to recurrence after curative surgery and prognosis in stage III colorectal cancer (2015) (0)
- ID: 3518404 METACHRONOUS GASTRIC CANCER AFTER CURATIVE ENDOSCOPIC SUBMUCOSAL DISSECTION OF INTESTINAL-TYPE EARLY GASTRIC CANCER: POST HOC ANALYSIS OF JCOG0607 (2021) (0)
- 2152 Exploratory analysis of predictive biomarkers of oxaliplatin versus irinotecan in combination with bevacizumab for patients with metastatic colorectal cancer in WJOG4407G study (2015) (0)
- P2-8-10Development of dosing recommendation of S-1 for patients with renal dysfunction by prospective pharmacokinetic study (2015) (0)
- CT image features of peritoneal metastasis and outcomes of the advanced gastric cancer patients receiving second-line chemotherapy. (2018) (0)
- The new prognostic index of advanced gastric cancer using the data from JCOG1013. (2023) (0)
- 1444P Real-world nivolumab safety data from 650 patients with unresectable advanced or recurrent gastric cancer that had progressed after cancer chemotherapy: Summary of post-marketing surveillance in Japan (2020) (0)
- Abstract 4468: In vitro evaluation of multi-targeted kinase inhibitors in scirrhous gastric cancer cell lines by tyrosine kinase activity profiling (2011) (0)
- 2125 Evaluation timing and cutoff value of tumor size (TS) ratio by using tumor growth inhibition (TGI) model to predict overall survival (OS) in metastatic colorectal cancer (mCRC) patients received first-line chemotherapy (CTx) (2015) (0)
- Preoperative docetaxel, cisplatin, and 5-fluorouracil for resectable esophagogastric junction adenocarcinoma: A retrospective study. (2021) (0)
- Outcomes of recurrence after complete response to definitive chemoradiotherapy for stage II/III (non–T4) esophageal squamous cell carcinoma. (2015) (0)
- The treatment strategy of the second-line chemotherapy for metastatic colorectal cancer (mCRC) patients (pts) with early progression in the first-line chemotherapy with bevacizumab (BEV), BEV beyond progression (BBP), or non-BBP. (2020) (0)
- O-089OUTCOMES OF SEGMENTECTOMY AND WEDGE RESECTION FOR PULMONARY COLORECTAL CANCER METASTASES (2016) (0)
- 1247 Phase I study of nimotuzumab, a humanized anti-epidermal growth factor receptor (EGFR) IgG1 monoclonal antibody in Japanese patients with solid tumors (2009) (0)
- O-6 Gene alterations in ctDNA related to the resistance mechanism of anti-EGFR antibodies and clinical efficacy outcomes of anti-EGFR antibody rechallenge plus trifluridine/tipiracil in metastatic colorectal cancer patients in WJOG8916G trial (2021) (0)
- P-83 The efficacy of chemotherapy for gastric cancer with early recurrence during or after adjuvant S-1 (2021) (0)
- 224PEvaluation of the safety and efficacy of combined the CART and chemotherapy for gastrointestinal cancers with massive ascites (2017) (0)
- IS2-5SYSTEMIC CHEMOTHERAPY FOR NEUCOENDOCRINE CARCINOMA OF THE GASTROINTESTINAL TRACT (2014) (0)
- Feasibility study of TAS-118 plus oxaliplatin as perioperative chemotherapy for patients with locally advanced gastric cancer (APOLLO-11). (2021) (0)
- Survival impact of post-progression chemotherapy (post-Cx) in advanced gastric cancer (AGC): Systematic review and meta-analysis. (2018) (0)
- The human equilibrative nucleoside transporter1 evaluated by SP120 and 10D7G2 had the potential to predict the prognosis in the patients with pancreatic cancer treated with adjuvant gemcitabine: Collaborative study of the JASPAC 01 trial (2019) (0)
- A phase II trial of combined treatment of endoscopic mucosal resection (EMR) and chemoradiotherapy (CRT) for clinical stage I esophageal squamous cell carcinoma (ESCC): Japan Clinical Oncology Group study JCOG0508. (2010) (0)
- Effectiveness of a facilitation programme using a mobile application for initiating advance care planning discussions between patients with advanced cancer and healthcare providers: protocol for a randomised controlled trial (J-SUPPORT 2104) (2023) (0)
- Clinicopathological differences between metachronous and synchronous multiple colorectal carcinomas (2000) (0)
- Phase II trial of adjuvant mFOLFOX6 after metastasectomy for pulmonary metastasis of colorectal cancer: WJOG5810G. (2020) (0)
- OS1. gastric cancer (2012) (0)
- 1252 POSTER First Report of the Safety, Tolerability, and Pharmacokinetics of Saracatinib (AZD0530) in Japanese Patients With Advanced Solid Tumours (2011) (0)
- Abstract CT052: Phase I study of the anti-heparin binding-EGF antibody U3-1565 with cetuximab in patients with cetuximab- or panitumumab-resistant metastatic colorectal cancer (2018) (0)
- 1251 Evaluation of pharmacokinetics and safety profiles between S-1 granule and S-1 capsule in patients with solid tumors (2009) (0)
- CLINICAL USEFULLNESS OF ENDOSCOPIC CLIPPING FOR DETERMINATION OF THE SURGICAL RESECTION LINE FOR EARLY GASTRIC CANCER (1999) (0)
- P1-6 Preoperative docetaxel, cisplatin, and 5-FU for resectable esophagogastric junction adenocarcinoma: Retrospective study (2021) (0)
- A meta-analysis with systematic review: Efficacy and safety of immune checkpoint inhibitors in patients with advanced gastric cancer (2022) (0)
- Correction to: Japan Society of Clinical Oncology Clinical Practice Guidelines 2017 for fertility preservation in childhood, adolescent, and young adult cancer patients: part 2 (2022) (0)
- Long-Term T oxicity A fter D efinitive C hemoradiotherap y f or Squamous C ell C arcinoma o f t he T horacic E sophagus (2003) (0)
- Chemoradiation Therapy for Esophageal Cancer : From the Point of Medical Oncology (2010) (0)
- Post-Marketing Survey of Panitumumab in Japanese Patients with Unresectable Colorectal Cancer: Interim Report of 3,005 Patients (2012) (0)
- Surrogate indicators of survival in patients who received neoadjuvant chemotherapy for type 4 and large type 3 gastric cancer in JCOG0501. (2020) (0)
- Feasibility and pathological response of TAS-118 + oxaliplatin as perioperative chemotherapy for patients with locally advanced gastric cancer (APOLLO-11). (2020) (0)
- Second-line chemotherapy with or without bevacizumab after early disease progression during first-line chemotherapy containing bevacizumab for patients with metastatic colorectal cancer (2021) (0)
- O1–045EFFICACY AND SAFETY OF GEMCITABINE PLUS CISPLATIN AS FIRST-LINE CHEMOTHERAPY FOR ADVANCED BILIARY TRACT CANCER (2013) (0)
- Comparison between local and extended field radiotherapy, including regional nodes radiotherapy, in combination with concurrent chemotherapy for T1bN0M0 esophageal cancer. (2017) (0)
- Regorafenib as second line therapy for imatinib-resistant gastrointestinal stromal tumor (GIST): A phase II study (2019) (0)
- Phase Ib study of andecaliximab (GS-5745, ADX) in combination with S-1+platinum chemotherapy in Japanese subjects with advanced gastric or GEJ adenocarcinoma. (2019) (0)
- Treatment for locally advanced esophageal carcinoma complicated by fistulas: Case report (1996) (0)
- Salvage chemotherapy versus best supportive care in patients with recurrent or metastatic squamous cell carcinoma of the esophagus refractory or intolerable to fluorouracil, platinum, and taxane. (2015) (0)
- Abstract 4248: Predictive signature of response to EGFR tyrosine kinase inhibitors in non-small-cell lung cancer cells by tyrosine kinase activity profiling (2014) (0)
- Preliminary result of p1/2 study of ramucirumab plus nivolumab in patients with pretreated advanced gastric carcinoma. (2018) (0)
- Abstract 668: Evaluation of α-1-acid glycoprotein as a prognostic marker and as a predictive biomarker for severe neutropenia induced by docetaxel in esophageal carcinoma patients (2017) (0)
- Primary analysis results of randomized controlled trial evaluating reactive topical corticosteroid strategies for the facial acneiform rash by EGFR inhibitors (EGFRIs) in patients (pts) with RAS wild-type (wt) metastatic colorectal cancer (mCRC): FAEISS study (2019) (0)
- [Diagnosis and treatment of pancreatic endocrine tumors]. (2009) (0)
- ASTUDY ON ENDOSCOPIC FINDINGS OF MUCINOUS CARCINOMA OF TIIE STOMACH (1999) (0)
- Randomized controlled phase III trial to investigate superiority of robot-assisted gastrectomy over laparoscopic gastrectomy for clinical stage T1-2N0-2 gastric cancer patients: Japan Clinical Oncology Group study JCOG1907 (MONA LISA study). (2021) (0)
- Impact of follow-up on generalized pairwise comparisons for estimating the irinotecan benefit in advanced/metastatic gastric cancer. (2021) (0)
- Abstract 3882: Exposure-toxicity analysis of unbound regorafenib and its active metabolites by dose escalation strategy with low starting dose in patients with colorectal cancer (2019) (0)
- 128PDetection of esophageal cancer patients using circulating serum microRNA from the result of comprehensive analysis (2017) (0)
- The use of trastuzumab in Japanese patients with HER2-positive advanced or metastatic gastric cancer. (2011) (0)
- 448TiP A multicenter single arm phase II trial evaluating the safety and the efficacy of panitumumab and irinotecan for patients with NeoRAS wild-type metastatic colorectal cancer (C-PROWESS trial) (2022) (0)
- A multi-institutional observational study evaluating the incidence and the clinicopathological characteristics of NeoRAS wild-type metastatic colorectal cancer. (2023) (0)
- 1419 POSTER Identification of a Protein Kinase Activity Based Biomarker Fingerprint to Predict Response to Sunitinib, Sorafenib and Pazopanib in Scirrhous Gastric Cancer Cell Lines (2011) (0)
- Single-arm phase II trial to evaluate the safety of laparoscopic/robotic total gastrectomy with spleen-preserving splenic hilar dissection for locally advanced proximal gastric cancer that invades the greater curvature: JCOG1809. (2023) (0)
- Impact of response to preoperative chemotherapy on the outcome of pulmonary metastasectomy for colorectal cancer: Results of a retrospective multicenter study. (2018) (0)
- Prospective evaluation of a developed S-1 dosage formula based on renal function. (2019) (0)
- Comparison of model fit and discriminatory ability of M category as defined by the 7th and 8th editions of the tumor‐node‐metastasis classification of colorectal cancer and the 9th edition of the Japanese classification (2021) (0)
- Initial safety report of ACTS-CC trial (TRICC0706): A randomized phase III trial of UFT/LV versus S-1 as adjuvant therapy for stage III colon cancer. (2011) (0)
- Observational study of FOLFIRINOX (FFX) for unresectable/recurrent pancreatic cancer (PC) in Japanese patients (pts)(JASPAC 06): final results (2016) (0)
- A phase II study of preoperative chemotherapy with docetaxel, oxaliplatin, and S-1 followed by gastrectomy with D2 plus para-aortic nodal dissection for gastric cancer with extensive lymph node metastasis: JCOG1704. (2023) (0)
- Targeting myeloid villains in the treatment with immune checkpoint inhibitors in gastrointestinal cancer (2022) (0)
- Long-term toxicity and survival of definitive chemoradiotherapy (CRT) in patients (pts) with T4/M1LYM esophageal carcinoma. (2004) (0)
- Phase I I S tudy o f a C ombination o f I rinotecan a nd C isplatin Against M etastatic G astric C ancer (1999) (0)
- Reviewers (2010) (0)
- Fluoropyrimidine (F) alone versus F plus platinum (P) as first-line chemotherapy in patients (pts) with advanced gastric cancer (AGC) and severe peritoneal metastasis (SPM): A multicenter observational study. (2018) (0)
- Patterns of local-regional relapse after complete response by definitive chemoradiotherapy for stage II/III (non–T4) esophageal squamous cell carcinoma. (2015) (0)
- The association of renal function with safety and efficacy of cisplatin plus S-1 (CS) therapy and docetaxel plus cisplatin plus S-1 (DCS) therapy in patients with advanced gastric cancer (AGC): An additional analysis of JCOG1013. (0)
- Definitive C hemoradiotherap y f or T 4 a nd/or M 1 L ymph N ode Squamous C ell C arcinoma o f t he E sophagus (1999) (0)
- 2386 Association between the peripheral immune status of granulocytic myeloid-derived suppressor cells and progression-free survival chemotherapy (2015) (0)
- Evaluation of heterogeneities in baseline risks and treatment effects among hospitals: Additional result of JCOG9912 phase III trial for advanced gastric cancer (2008) (0)
- Identification of cancer hallmarks associated with benefit in advanced gastroesophageal adenocarcinoma patients treated with checkpoint blockade. (2020) (0)
- 6603 POSTER Prognostic Factors of 127 Patients With Advanced Small-bowel Adenocarcinoma Treated With Systemic Chemotherapy (2011) (0)
- Retrospective analysis of first-line chemotherapy in 132 patients with advanced small-bowel adenocarcinoma. (2011) (0)
- [Activity of Taxanes for advanced and recurrent pancreatic cancer]. (2006) (0)
- Correlation Between the Depth of Invasion and Hardness of Resected Gastric Carcinoma Specimens Using a New Ultrasound Tactile Sensor (1998) (0)
- 1238 POSTER Phase 1 Clinical Trial of Oral PPAR – Agonist Efatutazone (CS-7017) in Japanese Patients With Metastatic Solid Tumours (2011) (0)
- Correction to: Long‑term outcomes of patients with recurrent squamous cell carcinoma of the esophagus undergoing salvage endoscopic resection after definitive chemoradiotherapy (2020) (0)
- Efficacy and Safety of Chemoradiotherapy for Patients with Locoregional Lymph Node Recurrence of Esophageal Squamous Cell Carcinoma (2012) (0)
- Authors & Collaborators _ RAISE study (2015) (0)
- Adverse effects of cell-free and concentrated ascites reinfusion therapy for malignant ascites: a single-institute experience (2022) (0)
- Abstract 5456: FGF9 gene amplification can induce resistance to anti-EGFR therapy in colorectal cancer (2015) (0)
- A feasibility study of a new smartphone application for patients with cancer. (2017) (0)
- Pattern of disease progression during third-line or later chemotherapy with nivolumab associated with poor prognosis in advanced gastric cancer: a multicenter retrospective study in Japan (2022) (0)
- Identification of serum microRNAs predicting the response to nivolumab in patients with advanced gastric cancer (2018) (0)
- Case report: potential treatment of metastatic amphicrine carcinoma of the rectum with FOLFOXIRI chemotherapy (2020) (0)
- Late complication after gastrectomy for clinical stage I cancer: supplementary analysis of JCOG0912 (2022) (0)
- Abstract 3818: Identification of aFGFR3-TACC3fusion in esophageal cancer (2017) (0)
- FA03.01: LONG-TERM OUTCOMES OF PATIENTS WITH RECURRENT SQUAMOUS CELL CARCINOMA OF THE ESOPHAGUS UNDERGOING SALVAGE ENDOSCOPIC RESECTION (2018) (0)
- Correction to: Real-world safety and effectiveness of nivolumab in Japanese patients with unresectable advanced or recurrent gastric/gastroesophageal junction cancer that has progressed after chemotherapy: a postmarketing surveillance study (2021) (0)
- Prognostic Factors of Bone Metastases From Colorectal Cancer in the Era of Targeted Therapy (2022) (0)
- Survival impact of the response at twelve weeks in patients with advanced gastric cancer received first-line chemotherapy. (2019) (0)
- “Para‐lesional” Saline Injection Method for Assessment of Small Gastric Cancers by Endoscopic Ultrasonography (1996) (0)
- P2-4-53EGFR and HER2 signals play a salvage role in MEK1-mutated gastric cancer after MEK inhibition (2015) (0)
- Association of renal function with the safety and efficacy of cisplatin plus S-1 therapy and docetaxel plus cisplatin plus S-1 therapy in patients with advanced gastric cancer: an exploratory analysis of JCOG1013. (2021) (0)
- Final Analysis of Randomized Phase III Study WJOG4007 Comparing Irinotecan (CPT-11) with weekly Paclitaxel (WPTX) in advanced Gastric Cancer (AGC) Refractory to Chemotherapy (CT) of Fluoropyrimidine Plus Platinum (FP) (2012) (0)
- Is gastric cancer producing alpha-fetoprotein highly chemosensitive?; from clinical and molecular biological studies (1995) (0)
- Concordance of human equilibrative nucleoside transporter‐1 expressions between murine (10D7G2) and rabbit (SP120) antibodies and association with clinical outcomes of adjuvant chemotherapy for pancreatic cancer: A collaborative study from the JASPAC 01 trial (2021) (0)
- Retrospective observational study of salvage line ramucirumab monotherapy for patients with advanced gastric cancer (2020) (0)
- [New evidence of chemotherapy for gastrointestinal cancer]. (2008) (0)
- Role of reduction gastrectomy in patients with gastric cancer with a single non‐curable factor: Supplementary analysis of REGATTA trial (2023) (0)
- Final report of post-marketing survey of panitumumab in Japanese patients with unresectable advanced or recurrent colorectal cancer. (2013) (0)
- Final Report on Phase 1 Clinical Trial of Oral Pparгagonist Efatutazone (CS-7017) in Japanese Patients with Metastatic Solid Tumors (2012) (0)
- Second-line chemotherapy with or without bevacizumab after early disease progression during rst-line chemotherapy containing bevacizumab for patients with metastatic colorectal cancer (2021) (0)
- Efficacy of adjuvant chemotherapy after resection of pulmonary metastasis from colorectal cancer: A propensity score matching analysis. (2018) (0)
- 1504 Impact of worsening in patient reported symptomatic adverse events (AEs) on deterioration of daily assessed quality of life(QOL) in cancer patients receiving initial chemotherapy; prospective exploratory study (2015) (0)
- Integration of pharmacoproteomic and computational approaches reveals the cellular signal transduction pathways affected by apatinib in gastric cancer cell lines. (2023) (0)
- Correlation Between the Effects of First-Line Chemotherapy and Survival Time from Second-Line Chemotherapy in Patients with Advanced Gastric Cancer (2012) (0)
- P1-5-16Exploratory analysis of prognostic subset in esophageal cancer patients previously treated with FU, Pt, taxane therapy (2015) (0)
- Efficacy of second-line treatment and prognostic factors in patients with advanced malignant peritoneal mesothelioma: a retrospective study (2021) (0)
- MO5-2 Retrospective study of nivolumab monotherapy for advanced esophageal squamous cell carcinoma (2021) (0)
- Plasma VEGF-A (pVEGF-A) level in efficacy analysis of metastatic colorectal cancer patients (mCRC) treated with mFOLFOX6/XELOX plus bevacizumab (BV) (WJOG7612GTR). (2018) (0)
- A Biomarker Analysis of Nivolumab in Previously Treated Advanced Gastric Cancer (WJOG10417GTR) (2019) (0)
- [Revision of the informed consent form for patients based on investigation of adverse events of mFOLFOX6 regimen]. (2009) (0)
- The association of renal function with safety and efficacy of cisplatin plus S-1 (CS) therapy and docetaxel plus cisplatin plus S-1 (DCS) therapy in patients with advanced gastric cancer (AGC): An exploratory analysis of JCOG1013. (2021) (0)
- A case of advanced gastric cancer complicated by severe toxicity induced by a combination of tegafur, uracil and mitomycin C, and associated with abnormal pharmacokinetics. (1996) (0)
- Esophageal Cancer: Esophageal Cancer Drug Therapy (2012) (0)
- Phase I/II trial of chemoradiotherapy concurrent with S-1 and cisplatin in patients with clinical stage II/III esophageal carcinoma: Results of the Japan Clinical Oncology Group study JCOG 0604. (2014) (0)
- Is Adjuvant Chemoradiotherapy Necessary for High-Risk Oropharyngeal Cancer after Surgery? (2012) (0)
- O3-7-4Risk Factor Analyses of Severe Cicatricial Stricture after Chemoradiotherapy for Stage II/III (T3) Esophageal Carcinoma (2017) (0)
- Clinical outcome of salvage chemotherapy after oxaliplatin based chemotherapy for metastatic small bowel adenocarcinoma (2019) (0)
- Confirmative study of incidence of flat/depressed type in newly detected metachronows earty colorectal carcinomas (2001) (0)
- 771TiPA feasibility study of TAS-118 plus oxaliplatin as perioperative chemotherapy for locally advanced gastric cancer (2017) (0)
- Discrepancy between physician-assessed and patient-reported oxaliplatin-induced peripheral neuropathy in patients with metastatic colorectal cancer who received mFOLFOX6 plus bevacizumab: A post-hoc analysis (WJOG4407GSS2). (2018) (0)
- 1399P Risk factors for body weight loss after gastrectomy for gastric cancer analysed from the JCOG1001 phase III trial (2021) (0)
- Influence of precedent drug on the subsequent therapy in the sequence of trifluridine/tipiracil with/out bevacizumab and regorafenib for unresectable or recurrent colorectal cancer (2022) (0)
- Primary Tumor-Related Complications Among Patients With Unresectable Stage IV Colorectal Cancer in the Era of Targeted Therapy: A Competing Risk Regression Analysis (2021) (0)
- 1212 A novel mitotic kinesin Eg5 inhibitor exerts the growth inhibitory effect on cancer cells in a manner independent of neither Eg5 expression level nor induction of monoastral formation (2009) (0)
- Multicenter retrospective analysis for elderly patients with advanced gastric cancer (AGC) received first-line chemotherapy in clinical practice. (2015) (0)
- Randomized Phase III Study of Irinotecan (CPT-11) Versus Weekly Paclitaxel (WPTX) for Advanced Gastric Cancer (AGC) Refractory to Combination Chemotherapy (CT) of Fluoropyrimidine Plus Platinum (FP): WJOG4007 Trial (2012) (0)
- Shorter survival in adolescent and young adult patients, compared to adult patients, with stage IV colorectal cancer in Japan (2018) (0)
- 406 Identification of an immunological prognostic factor for metastatic colorectal cancer patients treated with first-line oxaliplatin-based chemotherapy (2015) (0)
- Fluoropyrimidine with or without platinum as first-line chemotherapy in patients with advanced gastric cancer and severe peritoneal metastasis: a multicenter retrospective study (2019) (0)
- 2077 Prognostic index predicting the surgical outcome of pulmonary metastasis from colorectal cancer: Results of a retrospective Japanese multicenter study (2015) (0)
- Progression patterns and site-specific responses in advanced gastric cancer patients treated with nivolumab. (2023) (0)
- Clinical significance of serum factors relating to ERBB signal pathways in a phase II trial of S-1 plus cisplatin combined with trastuzumab for HER2-positive advanced gastric or esophagogastric junction cancer: WJOG7212G (T-SPACE) TR study (2016) (0)
- Clinical outcomes of resectable small bowel adenocarcinoma treated by surgery alone: Case series in a Japanese single institution. (2016) (0)
- Effect of definitive radiotherapy alone for the patients with esophageal squamous cell carcinoma (2019) (0)
- Reviewers (2005) (0)
- 584PPredictive value of primary tumor location: Results from randomized phase II study of panitumumab + irinotecan versus cetuximab + irinotecan in patients with KRAS exon2 wild-type metastatic colorectal cancer (WJOG6510G) (2017) (0)
- Application of the RTOG recursive partitioning analysis classification to brain metastases from colorectal cancer (2007) (0)
- Abstract 4430: A novel mitotic kinesin Eg5 inhibitor exerts the growth-inhibitory effect in cancer cells in a manner independent of induction of monoastral formation but dependent onKRASmutation status (2010) (0)
- Correction to: Indications for fertility preservation not included in the 2017 Japan Society of Clinical Oncology Guideline for Fertility Preservation in Pediatric, Adolescent, and Young Adult Patients treated with gonadal toxicity, including benign diseases (2022) (0)
- JASPAC 06: Observational study of FOLFIRINOX therapy for unresectable and recurrent pancreatic cancer—Preliminary report on serious adverse events. (2016) (0)
- How can we improve adjuvant chemotherapy for colon cancer? (2014) (0)
- Perioperative TAS-118 plus oxaliplatin in patients with locally advanced gastric cancer: APOLLO-11 study. (2023) (0)
- 2nd line bevacizumab(BEV) continuation chemotherapy(Cx) beyond early progression for metastatic colorectal cancer(mCRC) (2019) (0)
- Usefulness of an S-1 dosage formula: an exploratory analysis of randomized clinical trial (JCOG1001) (2022) (0)
- Development of dosing recommendation of S-1 for patients with impaired renal function by prospective pharmacokinetic study. (2015) (0)
- A phase II study to explore biomarkers for the use of mFOLFOX6/XELOX plus bevacizumab as a first-line chemotherapy in patients with metastatic colorectal cancer (WJOG7612GTR) (2022) (0)
- Abstract 4655:In vitrotyrosine kinase activity profiling to identify molecular targets and predictive biomarkers in gastric cancer cell lines. (2013) (0)
- 1417P Prediction of the peritoneal recurrence by macroscopic diagnosis of the serosal invasion in gastric cancer: Supplementary analysis of JCOG0110 study (2021) (0)
- Survival results by the prospectively determined clinical staging for locally advanced gastric cancer: An ancillary study of JCOG1302A (JCOG1302A2). (2023) (0)
- Comparison between S-1 monotherapy and S-1 plus cisplatin as postoperative chemotherapy after R0 resection for stage IV gastric cancer patients with oligometastasis: A multicenter retrospective study. (2019) (0)
- Thanking All Peer Reviewers. (2019) (0)
- SO-19 A multicenter phase Ⅱ trial of trifluridine/tipiracil in combination with cetuximab in RAS wild-type metastatic colorectal cancer patients refractory to prior anti-EGFR antibody therapy: The WJOG8916G trial (2021) (0)
- [Globalization of anti-cancer therapies]. (2002) (0)
- Impact of peripheral neuropathy induced by platinum in first-line chemotherapy on second-line chemotherapy containing paclitaxel for advanced gastric cancer. (2019) (0)
- Phase I study of cediranib in combination with cisplatin plus fluoropyrimidine (S-1 or capecitabine) in Japanese patients (pts) with untreated advanced gastric cancer (AGC). (2011) (0)
- 772TiPA phase 1/2 study of ramucirumab plus nivolumab in patients with previously treated advanced gastric adenocarcinoma (2017) (0)
- Tumor growth rate during re-challenge chemotherapy with previously used agents as salvage treatment for metastatic colorectal cancer: A retrospective study (2021) (0)
- Prospective evaluation of regorafenib dose escalation strategy with low starting dose in patients with colorectal cancer. (2018) (0)
- Final results of the ACTS-CC 02 trial: A randomized phase III trial of S-1/oxaliplatin (SOX) versus UFT/leucovorin as adjuvant chemotherapy for high-risk stage III colon cancer. (2021) (0)
- O-9 Phase 3 study to evaluate the efficacy and safety of naldemedine for the treatment of opioid-induced constipation (OIC) in cancer patients (2017) (0)
- How to detect superficial type of colorectal neoplasms? - From a retrospective and a prospective analyses of endoscopic findings (1995) (0)
- Thanking All Peer Reviewers. (2015) (0)
- S-1 and oxaliplatin versus tegafur-uracil and leucovorin as post-operative adjuvant chemotherapy in patients with high-risk stage III colon cancer: updated 5-year survival of the phase III ACTS-CC 02 trial (2021) (0)
- Risk Factors of Severe Benign Cicatricial Stricture After Definitive Chemoradiation for Localized T3 Esophageal Carcinoma (2020) (0)
- Endoscopic Study of Differential Diagnosis between Benign Ulcers and Malignancies with Open Ulcers of the Stomach (1996) (0)
- Five-year follow-up results of a randomized phase III trial comparing 4 and 8 courses of S-1 adjuvant chemotherapy for pathological stage II gastric cancer: JCOG1104 (OPAS-1). (2023) (0)
- [Correlation between response and survival]. (2000) (0)
- A case of duodenal carcinoid tumor completely resected by endoscopic mucosal resection (1998) (0)
- Clinical implications of using both fluoropyrimidine and paclitaxel in patients with severe peritoneal metastasis of gastric cancer: A post hoc study of JCOG1108/WJOG7312G (2021) (0)
- Pneumonitis induced antineoplastic agents: Mortality and risk factors in 129 consecutive cases (2019) (0)
- Risk factors for FN, mucositis and esophagitis of combination chemotherapy with docetaxel, cisplatin, and 5-fluorouracil for esophageal cancer (2020) (0)
- A multicenter retrospective study of Paclitaxel vs. Paclitaxel plus Ramucirumab for advanced gastric cancer patients (2019) (0)
- Phase I study of cediranib, an oral, highly potent and selective VEGFR signaling inhibitor, in Japanese patients with advanced solid tumors (2007) (0)
- Phase I study of the anti-heparin-binding epidermal growth factor-like growth factor antibody U3-1565 with cetuximab in patients with cetuximab- or panitumumab-resistant metastatic colorectal cancer (2019) (0)
- Risk factor analyses of severe cicatricial stricture after chemoradiotherapy for stage II/III (T3) esophageal carcinoma. (2017) (0)
- Oxaliplatin (L-OHP) in combination with 5-fluorouracil (5-FU)/l-leucovorin (l-LV) on modified Roswell Park regimen as first-line treatment of advanced colorectal cancer (ACRC): A phase I/II study. (2004) (0)
- 1397P Prognostic impact of infectious complications: Exploratory analysis of JCOG0501 phase III trial (2021) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Narikazu Boku?
Narikazu Boku is affiliated with the following schools:
